

PATENT SPECIFICATION

(1) 1356834

1356834

- (21) Application No. 51086/71 (22) Filed 3 Nov. 1971
 (21) Application No. 18116/72 (22) Filed 19 April 1972
 (21) Application No. 30767/72 (22) Filed 30 June 1972
 (23) Complete Specification filed 27 Sept. 1972
 (44) Complete Specification published 19 June 1974
 (51) International Classification C07D 57/00; A61K 27/00; C07D 99/02
 (52) Index at acceptance

C2C 1343 136X 1372 1390 1494 1534 1535 1592 1600 1604
 1628 1693 213 215 220 221 225 226 22Y 246 247
 250 251 252 253 255 256 25Y 28X 290 292 29X
 29Y 305 30Y 311 313 314 31Y 321 323 326 327
 32Y 332 337 338 341 342 34Y 351 354 355 360
 361 364 365 366 367 368 36Y 37X 43X 440 453
 456 45Y 470 471 485 490 491 500 503 509 50Y
 574 579 584 594 620 621 623 624 626 628 62X
 62Y 634 644 650 652 656 657 658 65X 667 66X
 670 671 672 675 677 680 681 682 694 697 698



ERRATA

SPECIFICATION No. 1,356,834

Page 2, line 100, for ylacetic read yacetate
 Page 35, line 93, after pharmaceutically-
 insert acceptable salt thereof, and an
 inert pharmaceutically-


THE PATENT OFFICE
 25th February, 1975

25

described in and by the following statement:—

This invention relates to indole derivatives and more particularly it relates to new heterocyclic-indol-3-yl-carboxylic acid derivatives which possess anti-inflammatory, analgesic and antipyretic activity.

According to the invention there are provided compounds of the formula:—



wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, iso-quinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzthiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through

phenyl substituents; and R² stands for hydrogen or a C₁₋₅-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR¹ or —CH₂OR¹, wherein R¹ stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, di-C₁₋₅-alkylamino-C₁₋₅-alkoxy, (C₂₋₆-cycloalkyl)methoxy, amino, C₁₋₅-alkylamino, di-C₁₋₅-alkylamino, anilino, hydrazino or N-1,3-dicyclohexylureido radical, and R¹ stands for hydrogen or a C₁₋₆-alkanoyl radical; and R⁶ stands for hydrogen or a methylenedioxy or ethylenedioxy radical or not more than two substituents selected from C₁₋₅-alkoxy, C₁₋₅-alkyl, cycloalkyl of not more than 5 carbon atoms, and di-C₁₋₅-alkylamino radicals and halogen atoms; and pharmaceutically-acceptable salts thereof.

As stated above, the heterocyclic radical R¹ is linked to the nitrogen atom of the indole nucleus through one of its ring carbon atoms

30

35

40

45

50

SEE ERRATA SLIP ATTACHED

BEST AVAILABLE COPY

1356834

PATENT SPECIFICATION

(11) 1356834

- (21) Application No. 51086/71 (22) Filed 3 Nov. 1971
(21) Application No. 18116/72 (22) Filed 19 April 1972
(21) Application No. 30767/72 (22) Filed 30 June 1972
(23) Complete Specification filed 27 Sept. 1972
(44) Complete Specification published 19 June 1974
(51) International Classification C07D 57/00; A61K 27/00; C07D 99/02
(52) Index at acceptance

C2C 1343 136X 1372 1390 1494 1534 1535 1592 1600 1604
1628 1693 213 215 220 221 225 226 22Y 246 247
250 251 252 253 255 256 25Y 28X 290 292 29X
29Y 305 30Y 311 313 314 31Y 321 323 326 327
32Y 332 337 338 341 342 34Y 351 354 355 360
361 364 365 366 367 368 36Y 37X 43X 440 453
456 45Y 470 471 485 490 491 500 503 509 50Y
574 579 584 594 620 621 623 624 626 628 62X
62Y 634 644 650 652 656 657 658 65X 667 66X
670 671 672 675 677 680 681 682 694 697 698
71X 727 73Y 740 743 744 770 777 790 79Y BC
BD KD KG KQ LQ LT LZ ME MF ML NL
NS NT WD ZB
ASB 244 24X 24Y 275 27Y 381 38Y 392 420 423 42Y 440
441 442 44Y 450 451 453 45Y 460 46Y 480 482
483 484 48Y 491 49Y 500 502 504 50Y 511 51Y
520 522 524 52Y 531 53Y 542 54Y 550 551 552
554 556 55Y 566 56Y 575 576 57Y 586 58Y 595
596 59Y 616 61Y 640 64Y 650 654 656 65Y 660
66Y 670 67Y 77Y


(72) Inventors GEORGE RICHARD BIRCHALL, WALTER
HEPWORTH and STEPHEN COLLYER SMITH

(54) INDOLE DERIVATIVES

(71) We, IMPERIAL CHEMICAL INDUSTRIES LIMITED, Imperial Chemical House, Millbank, London SW1P 3JF, a British Company, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to indole derivatives and more particularly it relates to new heterocyclic-indol-3-yl-carboxylic acid derivatives which possess anti-inflammatory, analgesic and antipyretic activity.

According to the invention there are provided compounds of the formula:—



(i)

wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzthiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through

a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy, C₁₋₅-alkylthio, amino (—NH₂), halogen, trifluoromethyl, trichloromethyl and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR⁷ or —CH₂OR⁸, wherein R⁷ stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, di-C₁₋₅-alkylamino-C₁₋₅alkoxy, (C₂₋₆-cycloalkyl)methoxy, amino, C₁₋₅-alkylamino, di-C₁₋₅-alkylamino, anilino, hydrazino or N-1,3-dicyclohexylureido radical, and R⁸ stands for hydrogen or a C₁₋₆-alkanoyl radical; and R⁹ stands for hydrogen or a methylenedioxy or ethylenedioxy radical or not more than two substituents selected from C₁₋₅-alkoxy, C₁₋₅-alkyl, cycloalkyl of not more than 5 carbon atoms, and di-C₁₋₅-alkylamino radicals and halogen atoms; and pharmaceutically-acceptable salts thereof.

As stated above, the heterocyclic radical R¹ is linked to the nitrogen atom of the indole nucleus through one of its ring carbon atoms

25

30

35

40

45

50




SEE ERRATA SLIP ATTACHED

- which is conjugated with a ring nitrogen atom. Accordingly, it is to be understood that R¹ is linked to the nitrogen atom of the indole nucleus through one of the following 5 positions of the former:—
 when R¹ stands for a pyrimidinyl radical, through position 2, 4 or 6 thereof;
 when R¹ stands for a benzthiazolyl or benzoxazolyl radical, through position 2 10 thereof;
 when R¹ stands for a quinolyl or quinazolinyl radical, through position 2 or 4 thereof;
 when R¹ stands for a cinnolinyl radical, through position 4 thereof;
 15 when R¹ stands for a quinoxalinyl radical, through position 2 or 3 thereof; and
 when R¹ stands for an isoquinolyl radical, through position 1 thereof.
- It will be appreciated by those skilled in 20 the art that some of the compounds of the formula I possess at least one asymmetric carbon atom, for example this is the case if R² and R⁴ are different. These asymmetric compounds may be resolved into the corresponding optically-active forms (i.e. enantiomeric forms) by conventional procedures. It 25 is to be understood that the racemates of the formula I possess anti-inflammatory, analgesic and antipyretic activity and that, in addition, 30 at least some of the optically active compounds of the formula I possess anti-inflammatory, analgesic and/or antipyretic activity. It is also to be understood that the compounds of this invention encompass both those compounds of the formula I which are racemates and the optically active compounds of the formula I which possess anti-inflammatory, analgesic and/or antipyretic activity.
- The substituent(s) which may optionally be 40 present in the heterocyclic radical R¹ may, for example, be selected from methyl, ethyl, isopropyl, methoxy, methylthio, amino, fluoro, chloro, bromo, trifluoromethyl, trichloromethyl and phenyl substituents.
- 45 A suitable value for R² when it stands for a C₁₋₃-alkyl radical is, for example, a methyl radical.
- A suitable value for R⁶ is, for example, 50 hydrogen or a methylenedioxy or ethylenedioxy radical or not more than two substituents selected from methoxy, ethoxy, propoxy, methyl, ethyl, propyl, butyl and dimethylamino radicals and fluorine, chlorine and bromine atoms.
- 55 A suitable value for R⁷ is, for example, a hydroxy, methoxy, ethoxy, propoxy, butoxy, 2-dimethylaminoethoxy, benzyloxy, phenoxy, cyclohexylmethoxy, amino, methylamino, dimethylamino, anilino, hydrazino or N-1,3-dicyclohexylureido radical.
- 60 A suitable value for R⁸ is, for example, hydrogen or a formyl, acetyl or propionyl radical. Thus, it is to be noted that for convenience in this specification the expression 65 "alkanoyl radical" includes a formyl radical.


Suitable salts of the invention in the case where the compound of the formula I is sufficiently basic are pharmaceutically-acceptable acid-addition salts, for example a hydrochloride, hydrobromide or citrate. A suitable salt in the case where R⁷ stands for a hydroxy radical is a salt in which the anion is derived from the said compound of the formula I and the cation is a pharmaceutically-acceptable cation, for example an alkali metal, alkaline earth metal, aluminium or ammonium salt, or a salt with a pharmaceutically-acceptable organic base, for example triethanolamine.

Particularly active compounds of the invention are 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, 1-(7-bromoquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, 1-(7-fluoroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, 5-methoxy-2-methylindol-3-ylacetic acid, 1-(2-methylquinazolin-4-yl)indol-3-ylacetic acid, 1-(7-chlorocinnolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, 1-(7-chloroquinazolin-4-yl)-2,5-dimethylindol-3-ylacetic acid, 1-(2,6-dimethoxypyrimidin-4-yl)-2,5-dimethylindol-3-ylacetic acid, 1-(7-chloroquinazolin-4-yl)-5-fluoro-2-methylindol-3-ylacetic acid, methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, methyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetate, and pharmaceutically acceptable salts thereof.

According to a further feature of the invention there is provided a process for the manufacture of the compounds of the formula I, wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings stated above except that R⁷ cannot stand for a hydrazino radical, and pharmaceutically-acceptable salts thereof, which comprises reacting a compound of the formula:—




wherein R¹ and R⁶ have the meanings stated above and Q stands for an amino radical (—NH₂) or a radical of the formula:—



wherein R⁹ stands for hydrogen or a methyl or ethyl radical, and R¹⁰ stands for a methyl,

3
ethyl or phenyl radical, or an acid-addition salt thereof, with a compound of the formula:—




5 wherein R^2 , R^3 , R^4 and R^5 have the meanings stated immediately above, under the influence of heat.

10 A suitable acid-addition salt of the compound of the formula II is for example, a hydrochloride, hydrobromide, sulphate or fluoroborate. The reaction may be carried out at, for example, 40 to 150°C, and more particularly 60 to 120°C. The reaction is preferably carried out in the presence of an acid, for example laevothalic acid (which is, of course, within the definition of the reactant of formula IV), acetic acid, or a relatively strong acid, for example hydrochloric, sulphuric, perchloric or polyphosphoric acid.

15 Under these conditions the reaction may optionally be carried out in a suitable solvent, for example water, a C_{1-4} -alkanol, for example ethanol, or acetic acid, or a mixture of any of these, and/or in an excess of a low melting compound of the formula IV, for example laevothalic acid.


20 It is to be understood that, when the starting material of the formula IV is a carboxylic acid and a C_{1-4} -alkanol is used as a solvent, the product is obtained as the corresponding alkyl ester. Alternatively, the reaction is preferably carried out in the presence of a Lewis acid, for example boron trifluoride etherate. A C_{1-4} -alkanol, for example methanol or ethanol, may optionally also be present, but in this case when the starting material of the formula IV is a carboxylic acid, the product is obtained as the corresponding alkyl ester.

25 40 Those of the starting materials of the formula II which are hydrazines may be obtained by reacting the appropriate phenylhydrazine of the formula:—



45 50 55 45 wherein R^6 has the meaning stated above, with a compound of the formula R^1Hal , wherein R^1 has the meaning stated above and Hal stands for a chlorine, bromine or iodine atom, in the presence of sodium acetate or a hydrate thereof, in the presence of a solvent, for example water, a C_{1-4} -alkanol, benzene or 1,2-dimethoxyethane. The remaining starting materials, that is, the hydrazones of the formula II, may be obtained by reacting the appropriate hydrazine of the formula II with the appropriate aldehyde or ketone of the formula $\text{R}^9\text{COR}^{10}$, wherein R^9 and R^{10}


have the meanings stated above. This reaction may be carried out in an excess of the said aldehyde or ketone and/or in the presence of an organic solvent, for example benzene or toluene. The reaction may optionally be catalysed by means of an inorganic or organic acid, for example sulphuric or acetic acid. However, a preferred method of making those of the said hydrazones wherein R^1 stands for a quinazolinyl or cinnolinyl radical comprises reacting a compound of the formula:—



(VI)

65 70 with a compound of the formula R^1Hal , under the influence of heat, for example under reflux, and in a dry organic solvent, for example 1,2-dimethoxyethane, and wherein R^6 , R^9 and Hal have the meanings stated above and R^1 has the meaning stated immediately above.

75 80 According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R^1 , R^2 , R^3 , R^4 and R^6 have the meanings stated above, and R^5 stands for a carboxy radical, and pharmaceutically-acceptable salts thereof, which comprises hydrolysing the corresponding compound of the formula:—




(VII)


85 90 wherein R^1 , R^2 , R^3 , R^4 and R^6 have the meanings stated above, and R^{11} stands for a cyano, carbamoyl, alkoxy carbonyl, benzyloxy carbonyl or phenoxy carbonyl radical.

95 100 105 A suitable hydrolytic agent is, for example, an alkali metal hydroxide, for example sodium hydroxide or potassium hydroxide. The hydrolysis is carried out in the presence of water, and optionally an organic solvent, for example a C_{1-4} -alkanol, for example ethanol, may be present. The reaction may optionally be accelerated or completed by the application of heat, for example it may be carried out at 50 to 150°C., for example at reflux temperature.

110 115 120 Those of the starting materials of the formula VII wherein R^{11} stands for a cyano radical, R^3 and R^4 stand for hydrogen, and R^1 , R^2 and R^6 have the meanings stated above, may be obtained by the following sequence of reactions:—



- 5 The amide starting materials of the formula VII (i.e. wherein R¹¹ stands for a carbamoyl radical) are formed as a by-product in the production of the nitriles of the formula XIII when made by the above sequence of reactions, and they may be obtained from the latter compounds by hydrolysis. The ester starting materials of the formula VII are obtainable by a process described hereinbefore.
- 10 According to a further feature of the invention there is provided a process for the manufacture of the compounds of the formula I, wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated above and R⁵ stands for a radical of the formula —COR' or CH₂OR', wherein R' has the meaning stated above and R⁸ stands for a C₂₋₆-alkanoyl radical, and pharmaceutically-acceptable salts thereof, which comprises dehydrogenating the corresponding indoline derivative of the formula: —
- 15
- 20



- 25 wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated above, and R⁵ has the meaning stated immediately above.
- It is to be understood that by the word "dehydrogenating" there is meant the removal of one hydrogen atom from the 2-position, and one from the 3-position, of the said 30 indoline derivative, so as to give the corresponding indole derivative. The dehydrogenation may be effected by means of a palladium on charcoal catalyst, for example a 35 of a suitable organic solvent, for example

diphenyl ether, at an elevated temperature, for example at or about reflux temperature. Alternatively, the dehydrogenation may be effected by means of a known compound having dehydrogenating properties, for example 2,3,5,6-tetrachloro-1,4-benzoquinone or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, in a suitable solvent, for example dry xylene, 1,2-dimethoxyethane or dimethylformamide, at 20 to 160°C., for example at reflux temperature.

The indoline starting materials of the formula XIV, except for the hydrazides wherein R⁵ stands for the group —CONHNH₂, may be obtained by using an analogous process to that outlined above for the production of the intermediates of the formula IX. The said hydrazides may be obtained by interaction of an appropriate ester of the formula XIV with hydrazine, by an analogous reaction to that described below.

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated above, and R⁵ stands for a radical of the formula —COR' wherein R' stands for a C₁₋₅-alkoxy, benzyloxy, di-C₁₋₅-alkylamino-C₁₋₅-alkoxy or (C₃₋₆-cycloalkyl)methoxy radical, and pharmaceutically-acceptable salts thereof, which comprises esterifying the corresponding carboxylic acid of the formula I wherein R⁶ stands for a carboxy radical, or a salt, acid halide or anhydride thereof.

The said esterification may be carried out by any appropriate general method, for example:

(1) By reacting the said carboxylic acid with the alcohol reactant, which may optionally be present in excess, in the presence of an acid,

40

45

50

55

60

65

70

75

for example a Lewis acid, for example boron trifluoride etherate, or sulphuric acid (this is not suitable in the case where R^1 stands for a quinazolinyl or cinnolinyl radical). This

- 5 reaction may conveniently be carried out at 40 to 120°C., for example under reflux.


(2) By reacting an acid halide, for example an acid chloride, or an acid anhydride (which expression includes a mixed acid anhydride) with the alcohol reactant. The reaction may be carried out in an excess of the alcohol reactant and/or in the presence of an organic solvent, for example chloroform, dimethylformamide, acetonitrile, tetrahydrofuran or 10 1,2-dimethoxyethane, and preferably the said alcohol reactant or organic solvent is used in a dry form. This reaction may conveniently be carried out at 20 to 100°C., for example under reflux.

(3) By reacting the said carboxylic acid with a carbodiimide, for example dicyclohexylcarbodiimide, and then, without isolation, reacting the product with the alcohol reactant. The reaction may be carried out in the presence of an organic solvent, for example chloroform, 1,2-dimethoxyethane, dimethylformamide, acetonitrile or tetrahydrofuran, and preferably the solvent is used in dry form. The reaction may conveniently be carried out at 20 to 100°C., preferably at room 15 20 25 30 35 40 45 temperature.

(4) By reacting a metal salt, for example a sodium salt, of the said carboxylic acid with a compound of the formula $R^{\prime}X$, which may optionally be in excess, wherein R' stands for a C_{1-6} -alkyl, benzyl, $di-C_{1-6}$ -alkylamino- C_{1-6} -alkyl or $(C_{3-6}$ -cycloalkyl)methyl radical, and X stands for a halogen atom, for example a chlorine, bromine or iodine atom, or a toluenesulphonyloxy or methanesulphonyloxy radical. The reaction may be carried out in the presence of an organic solvent, for example dimethylformamide, 1,2 - dimethoxyethane, acetonitrile or tetrahydrofuran, and preferably the solvent is used in dry form. The reaction may conveniently be carried out at 20 to 100°C. for example at room temperature.

According to a further feature of the invention there is provided a process for the manufacture of the compounds of the formula I, wherein R¹ stands for a quinazolinyl, cinnolinyl, benzoxazolyl or benzthiazolyl radical, which is linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in said radical, and which may optionally be substituted as stated above, and R⁵ stands for a radical of the formula —COR' or —CH₂OR', wherein R' stands for a C₁₋₁₂ alkoxy, benzylxy, phenoxy, di-C₁₋₅alkylamino-C₁₋₅-alkoxy or (C₁₋₅-cycloalkyl)methoxy radical and R⁸ stands for a C₁₋₁₂ alkanoyl radical, and R², R³, R⁴ and R⁶ have the meanings stated above, and pharmaceutically-acceptable salts thereof, which com-

prises reacting a compound of the formula:—




with a halogenoheterocyclic compound of the formula R^1Hal , wherein R^1 and R^5 have the meanings stated immediately above and R^2 , R^3 , R^4 , R^6 and Hal have the meanings stated above, in the presence of sodium or potassium or the hydride or amide thereof or n-butyl-lithium or lithium di-isopropylamide.


The process is conveniently carried out in a dry inert solvent, for example dimethylformamide or hexamethylenephosphorus triamide, and at 20 to 50°C.

The starting materials of the formula XV may be obtained by conventional procedures involving the acid-catalysed reaction of a compound of the formula IV with an appropriate compound of the formula II.

According to a further feature of the invention there is provided a process for the manufacture of the compounds of the formula I wherein R¹ stands for a quinazolinyl or cinnolinyl radical, which is linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in said radical, and which may optionally be substituted as stated above, and R⁵ stands for a radical of the formula —COR⁷ or —CH₂OR⁸, wherein R⁷ stands for a C₁₋₅-alkoxy, benzyloxy, phenoxy, di-C₁₋₅-alkylamino-C₁₋₅-alkoxy, (C₃₋₆-cycloalkyl)methoxy, amino, C₁₋₅-alkylamino, di-C₁₋₅-alkylamino, anilino or N-1,3-dicyclohexylureido radical and R⁸ stands for a C₂₋₆-alkanoyl radical, and R², R³, R⁴ and R⁶ have the meanings stated above, and pharmaceutically-acceptable salts thereof, which comprises reacting a compound of the formula: —



with a compound of the formula R^1Y , so as 105
to give a compound of the formula:—



and then ring-closing the said compound of the formula XVII so as to give the desired product of the formula I, and wherein R^1 110

- and R^5 have the meanings stated immediately above, R^2 , R^3 , R^4 and R^6 have the meanings stated above, and Y stands for a chlorine, bromine or iodine atom or a phenoxy radical.
- 5 The entire process is conveniently carried out in a dry, relatively high boiling, inert organic solvent, for example such a solvent of boiling point 50 to 200°C., for example 1,2-dimethoxyethane, diethyleneglycol dimethyl ether, dioxan, diphenyl ether or dimethylformamide. The first stage of the process is conveniently carried out at 20 to 100°C., and more particularly at 60 to 80°C. The ring-closure step is carried out by heating 10 the product of the formula XVII to elevated temperature, for example 40 to 150°C., for example reflux temperature, preferably under acidic conditions. Suitable acidic conditions are provided by the presence of the hydrogen 15 halide $HHal$ which is one product of the first stage of the process, i.e. the conversion of XVI into XVII. Alternatively, if desired, a relatively strong acid, for example hydrochloric, sulphuric, perchloric or polyphosphoric acid, or a Lewis acid, for example boron trifluoride etherate in the presence of an inert organic solvent, for example diethyl ether or tetrahydrofuran, or laevulinic or acetic acid, may be added to the reaction mixture.
- 20 30 The starting materials of the formula XVI may be obtained by reacting a phenylhydrazine derivative of the formula V, wherein R^6 has the meaning stated above, with a compound of the formula IV, wherein R^2 , R^3 , R^4 and R^5 have the meanings stated immediately above. The reaction may be carried out at 0 to 100°C., and more particularly at 25 to 50°C., and in a suitable organic solvent, for example a C_{1-4} -alkanol, for example ethanol, or benzene, 1,2-dimethoxyethane, or diethyl 35 ether. A catalytic quantity of an acid, for example acetic, sulphuric or perchloric acid, may optionally also be present.
- According to a further feature of the invention there is provided a process for the manufacture of compounds of the formula I, wherein R^1 , R^2 , R^3 , R^4 and R^6 have the meanings stated above and R^5 stands for a radical of the formula $-COR'$, wherein R' stands for an amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, anilino or hydrazino radical, and pharmaceutically-acceptable salts thereof, which comprises carrying out a known general process for making amides using as starting 40 material a carboxylic acid of the formula I wherein R^5 stands for a carboxy radical, or an acid halide, anhydride or nitrile thereof, so as to obtain the desired product.
- The said amides may be obtained, for 45 example, as follows:—
- (1) By reacting an appropriate ester, for example an ester of the formula I wherein R^5 stands for an alkoxy carbonyl radical, or an acid halide or anhydride (which term 50 includes a mixed acid anhydride) with a reactant of the formula $R'H$, wherein R' has the meaning stated immediately above. The process may be carried out in the presence of an organic solvent, for example dimethylformamide, chloroform, acetonitrile, tetrahydrofuran or 1,2-dimethoxyethane. In the case where R^5 stands for an alkoxy carbonyl radical, but not in the other cases, the solvent may be a C_{1-4} -alkanol. In the case where the reactant is an acid halide or anhydride, the solvent is preferably used in dry form. The process may be carried out at 55 20 to 100°C.; in the case where the reactant is an ester it is preferably carried out under reflux, but in the other cases it is preferably carried out at about room temperature.
- (2) By reacting the said carboxylic acid with a carbodiimide, for example dicyclohexylcarbodiimide, and then reacting the product with the reactant of the formula $R'H$, wherein R' has the meaning stated immediately above. The process is conveniently carried out in a dry organic solvent, for example dimethylformamide, tetrahydrofuran, chloroform, acetonitrile or 1,2-dimethoxyethane, at 20 to 100°C., preferably at room temperature.
- According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R^1 , R^2 , R^3 , R^4 and R^6 have the meanings stated above and R^5 stands for a radical of the formula $-COR'$ wherein R' stands for a N -1,3-dicyclohexylureido radical, and pharmaceutically-acceptable salts thereof, which comprises reacting the corresponding carboxylic acid of the formula I, wherein R^5 stands for a carboxy radical, with dicyclohexylcarbodiimide in a suitable organic solvent.
- A suitable solvent is, for example, 1,2-dimethoxyethane, and the process is conveniently carried out at room temperature.
- According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R^1 contains one or two C_{1-5} -alkoxy substituents, R^2 , R^3 , R^4 and R^6 have the meanings stated above, and R^5 stands for a carboxy or hydroxymethyl radical, and pharmaceutically-acceptable salts thereof, which comprises reacting the corresponding compound of the formula I, wherein R^1 contains one or two active halogen substituents, with an alkali metal derivative of a C_{1-5} -alkanol.
- By an "active halogen substituent" we mean a halogen substituent which, because of its chemical nature, its position in the said heterocyclic radical R^1 , and the chemical nature of said heterocyclic radical itself, is sufficiently active to take part in standard nucleophilic displacement reactions. Two examples of such active halogen substituents are the chlorine substituents in a 2,6-dichloropyrimid-4-yl radical. The reaction may be

carried out in an organic solvent, which can be the alkanol corresponding to the alkali metal alkoxide used as reactant. The reaction is conveniently carried out at 60 to 120°C., for example under reflux.

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹, R², R³, R⁴ and R⁵ have the meanings stated above, and R⁶ stands for a C₁₋₅-alkoxy radical optionally together with a C₁₋₅-alkyl, cycloalkyl of not more than 5 carbon atoms, di-C₁₋₅-alkylamino or halogeno substituent, and pharmaceutically-acceptable salts thereof, which comprises reacting the corresponding compound of the formula I, wherein R⁶ stands for a hydroxy radical, optionally together with an additional substituent as stated immediately above, or the corresponding alkali metal derivative (i.e. wherein an alkali metal atom replaces the hydrogen atom of the said hydroxy radical), with a compound of the formula R¹²X, wherein R¹² stands for a C₁₋₅-alkyl radical and X has the meaning stated above, and, in the case where the hydroxy derivative is used as reactant, in the presence of an acid-binding agent.

A suitable acid-binding agent is sodium or potassium hydride, or sodium or potassium carbonate. The reaction is conveniently carried out in a dry organic solvent, for example acetone, dimethylformamide, 1,2-dimethoxyethane or tetrahydrofuran.

The hydroxy derivatives used as starting material may be obtained by the debenzylation of the corresponding benzyloxy derivatives, either by hydrogenolysis, for example with hydrogen and a 10% w/w palladium on charcoal catalyst, or using a solution of hydrogen bromide in glacial acetic acid at 0 to 20°C.

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹ bears a fluorine, chlorine or bromine substituent and R², R³, R⁴, R⁵ and R⁶ have the meanings stated above, apart from the case where R⁷ stands for a hydrazino radical, and pharmaceutically-acceptable salts thereof, which comprises diazotising the corresponding compound of the formula I wherein R¹ bears an amino substituent, and then, in the case of the chloro or bromo substituent, reacting the diazonium salt with a solution of cuprous chloride or bromide in hydrochloric or hydrobromic acid respectively at 10 to 40°C., or, in the case of the fluoro substituent, thermally decomposing the dry diazonium fluoroborate salt at 40—100°C.

The diazotisation is carried out in conventional manner at a relatively low temperature, for example 0 to 5°C. In the case of the chloro or bromo substituent, the second stage

of the process is conveniently carried out at room temperature.

The amino derivatives used as starting materials may be obtained by reducing the corresponding nitro derivatives by means of hydrogen and a hydrogenation catalyst, for example a palladium on charcoal catalyst, and the nitro derivatives themselves may be obtained by the first process described herein.

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹, R², R³, R⁴ and R⁵ have the meanings stated above, and R⁶ stands for a hydroxymethyl radical, and pharmaceutically-acceptable salts thereof, which comprises reacting a corresponding ester of the formula I, wherein R⁵ stands for an alkoxy carbonyl, aralkoxy carbonyl or aryloxy carbonyl radical, with sodium borohydride, potassium borohydride or lithium aluminium hydride.

In the case of sodium or potassium borohydride, the reaction may be carried out in an organic solvent, for example a C₁₋₅-alkanol, for example methanol, and at a temperature of 20 to 120°C., for example under reflux. In the case of lithium aluminium hydride, a suitable solvent is dry tetrahydrofuran or ether. The esters used as starting materials may be obtained by methods described hereinbefore.

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹, R², R³, R⁴ and R⁵ have the meanings stated above and R⁶ stands for a radical of the formula —CH₂OR', wherein R⁶ stands for a C₁₋₅-alkanoyl radical, and pharmaceutically-acceptable salts thereof, which comprises acylating the corresponding compound of the formula I wherein R⁵ stands for a hydroxymethyl radical.

The acylation may be carried out in conventional manner, for example, in the case where R' stands for a C₂₋₅-alkanoyl radical, the acylation may be carried out by reacting the said hydroxy derivative with an acid halide or anhydride, for example acetic anhydride, optionally in the presence of an organic solvent. The reaction may be accelerated or completed by the application of heat. In the case where R' stands for a formyl radical, the acylation may be carried out, for example, by reacting the said hydroxy derivative with a C₁₋₅-alkyl formate, for example ethyl formate, which alkyl formate may optionally be present in excess, in the presence of a catalytic amount of an acid, for example sulphuric acid or a Lewis acid. Alternatively, the formates may be obtained by reacting the said hydroxy derivative with formic acid. Both formylation reactions may be accelerated or completed by the application of heat.

The pharmaceutically-acceptable salts of

70

75

80

85

90

95

100

105

110

115

120

125

130

the invention are obtained by conventional procedures.

The anti-inflammatory activity of the compounds of the invention has been demonstrated in two well known tests involving adjuvant induced arthritis and carrageenin induced oedema in the rat, their analgesic activity has been demonstrated in the so-called mouse squirm test and in another test involving established arthritis in rats, and their anti-pyretic activity has been demonstrated in a standard antipyretic test in rats. The activity in these tests depends upon the chemical structure of the particular compound being tested, but generally speaking the compounds of this invention show activity at a dose in the region 0.5 to 100mg./kg. No toxic effects or undesirable side effects have been observed in the rat or mouse with the compounds of the invention, at doses at which the compounds show activity in the above-mentioned tests.

When a compound of the invention is used as an anti-inflammatory, analgesic or anti-pyretic agent in the treatment of warm-blooded mammals, for example man, for example for the treatment of rheumatoid arthritis, it is recommended that said compound be administered orally at a total daily dose of 25 to 1000mg. per 70kg. bodyweight, for example as an aqueous or non-aqueous solution or suspension or as a dosage unit form, for example a tablet or capsule comprising 5 to 250mg. of the said compound. Alternatively, the said compound may be dosed rectally as a suppository at a total daily dose of 25 to 1000mg. per 70kg. bodyweight, or it may be administered topically as necessary.

According to a further feature of the invention there are provided pharmaceutical compositions comprising a compound of the formula I, wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings stated above, or a pharmaceutically-acceptable salt thereof, and an inert pharmaceutically-acceptable diluent or carrier.

The said pharmaceutical compositions may be in the form of, for example, dosage unit forms, for example tablets or capsules, or suppositories, aqueous or non-aqueous solutions or suspensions, sterile injectable aqueous or non-aqueous solutions, creams, lotions or ointments. The compositions are obtainable in a conventional manner using conventional diluents and carriers.

The pharmaceutical compositions of the invention may contain, in addition to a compound of the invention, at least one known agent having anti-inflammatory and/or analgesic activity, for example aspirin, paracetamol, codeine, chloroquine, phenylbutazone, oxyphenbutazone, indomethacin, mefenamic acid, flufenamic acid, ibufenac, or an anti-inflammatory steroid, for example prednisolone. Those compositions intended for oral administration may, in addition, optionally

contain at least one antacid, for example aluminium hydroxide, and/or a uricosuric agent, for example probenecid.

The invention is illustrated by the following non-limiting Examples:—

Example 1.

N - Phenyl - *N* - (2 - amino - 6 - methylpyrimidin - 4 - yl)hydrazine (7g) was suspended in laevulinic acid (25g.), and the mixture was heated at 100°C. for 1 hour whilst a stream of dry hydrogen chloride was passed through it. The mixture was then heated for a further 5 hours at 100°C. and, after cooling, it was diluted with ethyl acetate (150ml.). The resulting precipitate was collected by filtration and washed with ether (150ml.). The solid was suspended in hot water (150ml.; *ca* 70°C.), and aqueous ammonium hydroxide (D = 0.880) was added until the pH of the solution was 10. The resulting mixture was filtered, and, whilst it was still hot, the filtrate carefully acidified with glacial acetic acid until no further precipitate was obtained. The mixture was cooled to room temperature and then filtered. The solid residue was added to methanol (100ml.), the mixture heated under reflux for 30 minutes, and then cooled and filtered. The solid residue was crystallised from methanol (300ml.), and there was thus obtained 1-(2-amino - 6 - methylpyrimidin - 4 - yl) - 2-methylindol-3-ylacetic acid, m.p. 154—155°C. (decomposition).

The hydrazine derivative used as starting material was obtained as follows:—

A mixture of phenylhydrazine (66ml.), 2-amino - 4 - chloro - 6 - methylpyrimidine (86g.), and sodium acetate trihydrate (120g.) in water (2 l) was heated under reflux for 16 hours. The mixture was cooled, and adjusted to pH 9.0 by the addition of 40% w/v aqueous sodium hydroxide. The resulting precipitate was collected by filtration, and washed successively with water (2 l) and ethanol (200ml.). The solid was crystallised from ethanol to give *N*-phenyl-*N*-(2-amino-6 - methylpyrimidin - 4 - yl)hydrazine, m.p. 173—174°C.

Example 2.

A mixture of *N*-phenyl-*N*-(2,6-dichloropyrimidin-4-yl)hydrazine (30g.) and laevulinic acid (50g.) was heated at 100°C. for 3 hours whilst a stream of hydrogen chloride gas was passed through it. The mixture was cooled and added to water (400ml.), and the resulting mixture filtered to give 1-(2,6-dichloropyrimidin - 4 - yl) - 2 - methylindol - 3-ylacetic acid, m.p. 205—207°C.

The hydrazine derivative used as starting material was prepared as follows:—

A mixture of 2,4,6-trichloropyrimidine (50ml.) and phenylhydrazine (45ml.) was added to a solution of sodium acetate trihydrate (100g.) in water (270ml.) and ethanol

(720ml.). The resulting mixture was kept at room temperature for 3 days. The resulting crystalline precipitate was collected by filtration, washed with ethanol (100ml.) and dried at 60°C. to give *N*-phenyl-*N*-(2,6-dichloropyrimidin-4-yl)hydrazine, m.p. 114—116°C.

Example 3.

A mixture of 2-methyl-1-quinol-4-ylindol-3-ylacetonitrile and 2-methyl-1-quinol-4-ylindol-3-ylacetamide (obtained as described below) was dissolved in ethanol (50ml.). 10% w/v Aqueous potassium hydroxide (50ml.) was added, and the mixture was heated under reflux for 15 hours. The solvents were then evaporated *in vacuo*, and the residue was diluted with water (100ml.). The aqueous solution was washed with chloroform (3×50ml.) and then carefully acidified with 2N-hydrochloric acid to pH 5. The resulting mixture was filtered and the solid residue was washed with water and then dried at 60°C. There was thus obtained 2-methyl-1-quinol-4-ylindol-3-ylacetic acid, m.p. 235—240°C.

The mixture of nitrile and amide used as starting material was obtained as follows:—
A solution of 2-methylindoline (3.96g.) and 4,7-dichloroquinoline (5.91g.) in ethanol (100ml.) containing one drop of concentrated hydrochloric acid was heated under reflux for 4 hours. The solution was cooled, and to it was added a saturated solution of sodium acetate in ethanol (100ml.), followed by water (200ml.). The mixture was extracted with chloroform (2×50ml.), and the combined extracts were dried ($MgSO_4$) and evaporated to give 7-chloro-4-(2-methylindolin-1-yl)-quinoline as a yellow oil [the corresponding hydrochloride was obtained in conventional manner and had m.p. 248—250°C. (decomposition)].

A solution of 7-chloro-4-(2-methylindolin-1-yl)-quinoline (17g.) in diphenyl ether (50ml.) containing 10% w/w palladium on charcoal catalyst (6.5g.) was heated under reflux for 3 hours. The mixture was cooled and filtered, and the solid residue was extracted with hot chloroform (3×50ml.; *ca* 60°C.). The chloroform was evaporated *in vacuo* from the extract. The residue was chromatographed on a column of chromatographic silica gel (column dimensions: 20×3.5cm.) using a 1:3 v/v mixture of diethyl ether and petroleum ether (b.p. 40—60°C.) as eluant. The solvents were evaporated *in vacuo* from the eluate to give 4-(2-methylindol-1-yl)quinoline, m.p. 78—80°C.

A solution of 4-(2-methylindol-1-yl)-quinoline (6g.) in dioxan (50ml.) was added to 2N-acetic acid (50ml.) containing 37% w/v formalin solution (1.6g.) and 30% w/v aqueous dimethylamine solution (3.2g.). The

mixture was heated at 80°C. for 4 hours. A further quantity of 37% w/v formalin solution (1.6g.) and 30% w/v aqueous dimethylamine solution (3.2g.) were then added, and heating was maintained at 80°C. for a further 16 hours. The mixture was then evaporated *in vacuo* to dryness. 2N-Aqueous potassium hydroxide solution (50ml.) was added to the residue, and the mixture was extracted with chloroform (3×50ml.). The combined chloroform extracts were extracted with 4N-hydrochloric acid (3×50ml.). The combined acidic extracts were basified with 40% w/v aqueous potassium hydroxide solution, and then extracted with chloroform (3×50ml.). The combined chloroform extracts were dried ($MgSO_4$) and evaporated to yield an oil (6.8g.). To a solution of the oil in dry ethanol (50ml.) was added methyl iodide (3ml.), and the solution was stirred at room temperature for 20 hours. The precipitate which formed was filtered off and dried at 60°C. to give *N*-(1-quinol-4-yl-2-methylindol-3-ylmethyl)trimethylammonium iodide, m.p. 213—215°C. (decomposition).

A mixture of *N*-(1-quinol-4-yl-2-methylindol-3-ylmethyl)trimethylammonium iodide (6.5g.), potassium cyanide (10g.), 2-methoxyethanol (50ml.) and water (50ml.) was heated under reflux for 20 hours. The mixture was then cooled and diluted with water (150ml.), and the resulting mixture extracted with ethyl acetate (3×50ml.). The combined extracts were dried ($MgSO_4$) and evaporated *in vacuo* to give a mixture of 2-methyl-1-quinol-4-ylindol-3-ylacetonitrile and 2-methyl-1-quinol-4-ylindol-3-ylacetamide.

Example 4.

A mixture of ethyl 1-quinazolin-4-ylindolin-3-ylacetate (2.6g.) and 10% w/w palladium on charcoal catalyst (1.3g.) in diphenyl ether (20ml.) was heated under reflux for 30 minutes. The mixture was cooled to room temperature, mixed with diethyl ether (50ml.) and filtered through diatomaceous earth. The solid residue was washed with diethyl ether (50ml.). The combined diethyl ether solution was evaporated *in vacuo*, and the residue was chromatographed on silica gel (*ca* 150g.) using, as eluant, petroleum ether (b.p. 40—60°C.) containing an increasing proportion of diethyl ether. Diphenyl ether was recovered from the first fractions (rich in petroleum ether). Evaporation *in vacuo* of later fractions gave a syrup which crystallised from a mixture of diethyl ether and petroleum ether (b.p. 40—60°C.) to give ethyl 1-quinazolin-4-ylindol-3-ylacetate, m.p. 65—67°C.

In a similar manner, starting with the appropriate indoline derivative, there were obtained the following compounds:—

65

70

75

80

85

90

95


106

105

110

115

120



R^1	Characteristic Properties
quinazolin-4-yl	m.p. 121—123°C.
benzthiazol-2-yl	m.p. 158—160°C.
4-methyl-2-phenylpyrimidin-6-yl	m.p. 160—162°C.
quinol-4-yl (It should be noted that this product was obtained from the corresponding 7-chloroquinol-4-yl derivative described below; i.e. the 7-chlorine substituent was removed during the reaction).	NMR: —OCH ₃ , τ 6.15 Shown to be pure on thin layer chromatography (TLC) on silica gel; elution with 1:1 v/v ether:petroleum ether, b.p. 40—60°C.*
quinol-2-yl	NMR: —OCH ₃ , τ 6.12 Shown to be pure on TLC (system as above)

*Hereinafter referred to as system A.

- The ethyl 1-quinazolin-4-ylindolin-4-ylacetate used as starting material in this Example was obtained as follows:—
- 5 A mixture of 4-chloroquinazoline (2.3g.) and ethyl indolin-3-ylacetate (2.6g.) in 1,2-dimethoxyethane (30ml.) was heated under reflux for 15 minutes. The mixture was cooled and filtered, and the solid residue was dissolved in ice-water (40ml.). To the solution was added saturated sodium acetate solution (10ml.), and the mixture was extracted with ethyl acetate (\times 50ml.). The combined extracts were dried (Na₂SO₄), and the solvent evaporated *in vacuo* to give ethyl 1-quinazolin-4-ylindolin-3-ylacetate as a syrup which was proved to be pure by TLC (system A).
- 10 The ethyl 5-methoxy-2-methyl-1-quinazolin-4-ylindolin-3-ylacetate (m.p. 126—128°C.) used as starting material was prepared in analogous fashion from ethyl 5-methoxy-2-methylindolin-3-ylacetate.
- 15 The ethyl 5-methoxy-2-methyl-1-(4-methyl-2-phenylpyrimidin-6-yl)indolin-3-ylacetate used as starting material in this

Example was obtained as follows:—

A mixture of ethyl 5-methoxy-2-methylindolin-3-ylacetate (2.0g.), 6-chloro-4-methyl-2-phenylpyrimidine (1.76g.) and concentrated hydrochloric acid (0.5ml.) in ethanol (50ml.) was heated under reflux for 5 hours. The solution was cooled, saturated sodium acetate solution (3ml.) was added, and the mixture was concentrated *in vacuo*. The residue was diluted with water (30ml.) and extracted with ethyl acetate (3 \times 30ml.). The combined extracts were washed with water and then dried (Na₂SO₄), and the solvent was evaporated *in vacuo* at ca 50°C. to give ethyl 5-methoxy-2-methyl-1-(4-methyl-2-phenylpyrimidin-6-yl)indolin-3-ylacetate as a syrup. This was shown to be pure by TLC (System A) and by NMR spectroscopy (OCH₃ at 6.23 τ).


30 In a similar manner, starting with the appropriate chloroheterocyclic compound, the following indoline starting materials were obtained:—

35

40

45

45



R^1	Characteristic Properties
quinol-2-yl	NMR: $-\text{OCH}_3$, τ 6.20 Shown to be pure on TLC (System A)
7-chloroquinol-4-yl	NMR: $-\text{OCH}_3$, τ 6.18 Shown to be pure on TLC (System A)
benzthiazol-2-yl	m.p. 91—93°C.

Example 5.

A mixture of ethyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindolin-3-ylacetate (7.0g.) and 2,3,5,6-tetrachloro-1,4-benzoquinone (5.6g.) in dry xylene (50ml.) was heated under reflux for 1.5 hours. The mixture was then cooled and filtered. The filtrate was washed successively with cold 2N-sodium hydroxide solution ($2 \times 30\text{ml}$) and water ($2 \times 50\text{ml}$). The organic layer was dried (MgSO_4) and evaporated *in vacuo* to dryness, and the residue (dissolved in the minimum volume of diethyl ether) was adsorbed on a column of chromatographic silica gel (column dimensions: $15 \times 3.5\text{cm}$). The column was eluted with a 1:3 v/v mixture of diethyl ether and petroleum ether (b.p. 40—60°C.), and the eluate was evaporated *in vacuo* to give ethyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindolin-3-ylacetate as a yellow oil, NMR: $-\text{OCH}_3$, τ 6.12.

The preparation of the indoline derivative used as starting material is described in Example 4.

Example 6.

2N-Sodium hydroxide (50ml.) was added to a solution of ethyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindolin-3-ylacetate (2g.) in ethanol (50ml.), and the mixture was heated at 80°C. for 15 minutes. The ethanol was evaporated *in vacuo*, and the residue was diluted with water (50ml.). The resulting mixture was filtered, and the solid residue was dissolved in water (30ml.). The solution was adjusted to pH 5 with concentrated hydrochloric acid, and the resulting precipitate was filtered off and dried at 60°C. There was thus obtained 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindolin-3-ylacetic acid, m.p. 248—250°C.

Example 7.

A mixture of ethyl 5-methoxy-2-methyl-1-quinol-4-ylindol-3-ylacetate (1.8g.), ethanol (25ml.) and 2N-potassium hydroxide (25ml.) was heated under reflux for 15 minutes. Most of the ethanol was then evaporated *in vacuo*, and the residue was diluted with water (100ml.). The resulting mixture was filtered and the filtrate acidified to pH 5 with 2N-hydrochloric acid. The resulting mixture was filtered, and the solid residue was washed with water ($2 \times 20\text{ml}$) and dried at 60°C. There was thus obtained 5-methoxy-2-methyl-1-quinol-4-ylindol-3-ylacetic acid, m.p. 262—265°C.

Similarly, from ethyl 5-methoxy-2-methyl-1-quinol-2-ylindol-3-ylacetate there was obtained 5-methoxy-2-methyl-1-quinol-2-ylindol-3-ylacetic acid, m.p. 173—175°C., and from ethyl 5-methoxy-2-methyl-1-quinazolin-4-ylindol-3-ylacetate there was obtained 5-methoxy-2-methyl-1-quinazolin-4-ylindol-3-ylacetic acid monohydrate, m.p. 101—103°C.

Example 8.

The method described in Example 4 was carried out using ethyl 5-methoxy-2-methyl-1-(2-phenylquinol-4-yl)indolin-3-ylacetate as starting material. There was thus obtained ethyl 5-methoxy-2-methyl-1-(2-phenylquinol-4-yl)indolin-3-ylacetate, NMR: $-\text{OCH}_3$, τ 6.12. The product was shown to be pure by TLC on silica gel; elution with 5:1 ether: petroleum ether (b.p. 40—60°C.).

The indoline derivative used as starting material was obtained by the method described above in respect of compounds of the formula XII, and it had NMR: $-\text{OCH}_3$, τ 6.15. It

45

50

55

60

65

70

75

80

was shown to be pure by TLC on silica gel; elution with 1:1 ether: petroleum ether (b.p. 40-60°C.).

Example 9.

5 In a similar manner to that described in Example 5, starting with methyl 1-(7-chloroquinol - 4 - yl) - 2 - methylindolin - 3 - ylacetate, there was obtained methyl 1-(7-chloroquinol - 4 - yl) - 2 - methylindolin - 3 - ylacetate as an oil, NMR: $-\text{OCH}_3 \tau 6.21$.


10 In a similar manner, using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone instead of 2,3,5,6 - tetrachloro - 1,4 - benzoquinone, from ethyl 1-(6-chloro-4-methylquinol-2-yl)-15 5 - methoxy - 2 - methylindolin - 3 - yl-

acetate, there was obtained ethyl 1-(6-chloro-4 - methylquinol - 2 - yl) - 5 - methoxy - 2 - methylindolin-3-ylacetate, m.p. 137-138°C., and from ethyl 1-(7-chloro-2-methylquinol-4-yl) - 5 - methoxy - 2 - methylindolin - 3 - ylacetate there was obtained ethyl 1-(7-chloro - 2 - methylquinol - 4 - yl) - 5 - methoxy - 2 - methylindolin - 3 - ylacetate as an oil, NMR: $-\text{OCH}_3 \tau 6.17$.

20 The following indoline derivatives used as starting materials were prepared in a similar manner to that described in Example 4 for the preparation of ethyl 5-methoxy-2-methyl-1 - (4 - methyl - 2 - phenylpyrimidin - 6 - yl)indolin-3-ylacetate:—

25

30




R^1	R^7	R_6	Characteristic properties
7-chloroquinol-4-yl	$-\text{OCH}_3$	H	NMR $-\text{OCH}_3 \tau 6.22$ Shown to be pure by TLC*
6-chloro-4-methyl-quinol-2-yl	$-\text{OCH}_2\text{CH}_3$	OCH_3	NMR $-\text{OCH}_3 \tau 6.15$ Shown to be pure by TLC*
7-chloro-2-methyl-quinol-4-yl	$-\text{OCH}_2\text{CH}_3$	OCH_3	NMR $-\text{OCH}_3 \tau 6.18$ Shown to be pure by TLC*

*System A.

Example 10.

In analogous manner to that described in Example 7, the following compounds were

35 prepared from the appropriate methyl or ethyl ester:—



R^1	R^2	Characteristic properties
7-chloroquinazolin-4-yl	methoxy	m.p. 94—95°C. (hemihydrate)
6-chloro-4-methyl-quinol-2-yl	methoxy	m.p. 226—227°C. (monohydrate)
7-chloro-2-methyl-quinol-4-yl	methoxy	m.p. 258—259°C.
7-chloroquinol-4-yl	H	m.p. 113—115°C. (hemihydrate)
7-chlorocinnolin-4-yl	methoxy	m.p. 190—193°C. (dec.)
quinazolin-4-yl	H	m.p. 240—241°C. (dec.)

Example 11.

5 A solution of methyl 1-(7-chlorocinnolin-4-yl) - 5 - methoxy - 2 - methylindolin - 3 - ylacetate (7.9g.) in dry 1,2-dimethoxyethane [80ml.; dried over sodium alumino-silicate (molecular sieve type 4A; obtainable from BDH Chemicals Ltd., Poole, England)] was mixed with a solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (4.5g.) in dry 1,2-dimethoxyethane (30ml.). The solution was heated under reflux for 20 minutes and then evaporated *in vacuo*. The residue was extracted with chloroform (5×50ml.). Evaporation of the extracts gave an oil, which was purified by chromatography on silica gel (350g.), using ether as eluant, to give methyl 1 - (7 - chlorocinnolin - 4 - yl) - 5 - methoxy-2-methylindol-3-ylacetate as a red syrup, homogeneous by thin layer chromatography

(ether: silica gel) [hereinafter referred to as system C], and having a satisfactory NMR spectrum ($-\text{OCH}_3$, τ 6.13).


10 In a similar manner there were obtained from the appropriate indoline derivatives: methyl 1 (7 - chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate (m.p. 112—114°C.), methyl 1-(6,8-dichloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol-3-ylacetate (m.p. 135—137°C.), and methyl 2 - methyl - 1 - quinazolin - 4 - ylindol-3-ylacetate [syrup, pure by TLC (systems A and C) and NMR spectroscopy ($-\text{OCH}_3$, τ 6.1)].

15 The indoline derivatives used as starting materials were prepared in a similar manner to ethyl 1-quinazolin-4-ylindolin-3-ylacetate, as described in Example 4:—

25

30

35



(xxii)

R^6	R^1	Characteristic properties
CH_3O	7-chlorocinnolin-4-yl	orange syrup; NMR: $-OCH_3$ at 6.15τ ; shown to be pure by TLC (System C)
CH_3O	7-chloroquinazolin-4-yl	yellow syrup; NMR: $-OCH_3$ at 6.13τ ; shown to be pure by TLC (System A)
H	quinazolin-4-yl	yellow solid; m.p. 109—110°C.; pure by TLC (Systems A and C)
CH_3O	6,8-dichloroquinazolin-4-yl	yellow syrup; pure by TLC (Systems A and C)

Example 12.

5 - Methoxy - 2 - methyl - 1 - quinol - 4 - ylindol-3-ylacetic acid (2g.) in methanol (30mL) containing concentrated sulphuric acid (1 mL.) was refluxed for 2 hours. The resulting red solution was treated with saturated methanolic sodium acetate solution (30mL) and the methanol then evaporated *in vacuo*. The residue was diluted with water (50mL) and extracted with diethyl ether (2 \times 30mL.). The ether extracts were dried ($MgSO_4$) and evaporated, to yield methyl 5-methoxy-2-methyl - 1 - quinol - 4 - ylindol - 3 - ylacetate, m.p. 103—105°C.

Example 13.

Ethyl 5 - methoxy - 2 - methyl - 1 - (2-phenylquinol - 4 - yl)indol - 3 - ylacetate (2.1g.) in ethanol (20mL) and 2N-sodium hydroxide solution (20mL) was refluxed for 0.25 hour. Most of the ethanol was removed *in vacuo* and the residue was diluted with water (50mL). The resulting mixture was filtered, and the residue was washed with water and dried at 60°C. to give 5-methoxy-2 - methyl-1 - (2 - phenylquinol - 4 - yl)indol-3-ylacetic acid sodium salt monohydrate, m.p. 179—180°C.

Example 14.

30 A mixture of 1-(7-chloroquinol-4-yl)-5-methoxy - 2 - methylindolin - 3 - ylacetate (1g.) and 2,3,5,6-tetrachloro-1,4-benzoquinone (1g.) in dry xylene (50mL) was refluxed for 2 hours. The solvent was removed

35 *in vacuo* and the residue adsorbed on a column of chromatographic silica gel (50g.). The column was eluted with chloroform containing increasing amounts of methanol (starting with pure chloroform, and then using increments of 1% v/v of methanol in chloroform; product mainly eluted with 5% methanol in chloroform) to give 1-(7-chloroquinol - 4 - yl) - 5 - methoxy - 2 - methylindol-3-ylacetic acid, m.p. 248—250°C.

40 The indoline derivative used as starting material was prepared from ethyl 1-(7-chloroquinol - 4 - yl) - 5 - methoxy - 2 - methylindolin-3-ylacetate in a similar manner to that described in Example 7; it had m.p. 248—250°C.

Example 15.

45 A solution of methyl 1-(7-chloroquinazolin-4 - yl) - 5 - methoxy - 2 - methylindolin - 3 - ylacetate hydrochloride (2.15g.) in dry dimethylformamide (50mL; dried with calcium hydride) was treated with 2,3-dichloro - 5,6 - dicyano - 1,4 - benzoquinone (1.2g.). The mixture was heated on a steam bath for 2 hours and then an additional portion of the benzoquinone derivative (0.6g.) was added. After further heating for 1 hour, the solution was poured into water (500mL) containing anhydrous sodium acetate (10g.). The mixture was extracted with chloroform (3 \times 100mL) and the solid residue, at the solvent interface, discarded. The chloroform extracts were washed successively with water, saturated sodium bicarbonate solution, water

50

40

45

50

55

60

65

and brine, and then dried ($MgSO_4$). Evaporation of the solution gave an oil, which was purified by chromatography on silica gel (100g.) in an increasing gradient of ether in petroleum ether (b.p. 40—60°C.) (polarity increased by incremental addition of 10% v/v ether) to give methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate as a yellow solid, m.p. 112—114°C.

10 The starting material was prepared as follows:—

15 A mixture of methyl 5-methoxy-2-methylindolin-3-ylacetate (9.5g.) and 4,7-dichloroquinazoline (8.0g.) in dry 1,2-dimethoxyethane (100ml.; dried over sodium alumino-silicate, see Example 11) was heated under reflux for 1 hour. The mixture was cooled to 20—25°C. and the resulting mixture filtered to give methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindolin-3-ylacetate hydrochloride, m.p. 188—190°C. (decomposition).

Example 16.

25 A stirred suspension of sodium hydride (0.24g.) in dry dimethylformamide (20ml.; dried with calcium hydride) was treated at 5—10°C. with a solution of ethyl 2-methyl-5-methoxyindol-3-ylacetate (2.3g.) in dry dimethylformamide (10ml.). The mixture was stirred at 25—30°C. for 15 minutes, and the solution obtained was treated with a freshly prepared solution of 4-chloroquinazoline (1.65g.) in dry dimethylformamide (10ml.). The mixture was stirred at 30—40°C. for 4 hours, and then poured into water (500ml.). The mixture was extracted with ethyl acetate (4×100ml.) and the extracts washed successively with water (2×100ml.) and brine (100ml.), and then dried (sodium sulphate). 30 Evaporation of solvent gave an oil which was purified by chromatography on silica gel (250g.) using an increasing gradient of ether in petroleum ether (b.p. 40—60°C.) (the polarity increased by incremental addition of 10% v/v ether) to give ethyl 5-methoxy-2-methyl-1-(quinazolin-4-yl)indol-3-ylacetate, m.p. 121—123°C.

35 In a similar manner there was obtained methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate, m.p. 112—114°C., from the appropriate starting materials.

Example 17.

40 A solution of ethyl laevisulinate *p*-methoxyphenyl-hydrazone (2.64g.) in dry 1,2-dimethoxyethane (30ml.; dried over sodium alumino-silicate, see Example 11) was treated with a solution of 4-chloroquinazoline (1.7g.) in dry 1,2-dimethoxyethane (20ml.). The 45 resulting solution was heated under reflux for 4 hours and then concentrated *in vacuo*.

To the residue was added a saturated solution of sodium acetate (30ml.), and the mixture was extracted with ethyl acetate (50ml.). The aqueous phase was separated and further extracted with ethyl acetate (3×50ml.). The combined ethyl acetate extracts were washed successively with water (50ml.), saturated sodium bicarbonate solution (50ml.), water (50ml.) and brine (50ml.), and then dried (magnesium sulphate) and evaporated *in vacuo*. The residual syrup was chromatographed on silica (300g.) using an increasing gradient of ether petroleum ether (b.p. 40—60°C.) (polarity increased by incremental addition of 10% v/v ether) to give ethyl 5-methoxy-2-methyl-1-(quinazolin-4-yl)indol-3-ylacetate, m.p. 121—123°C.

50 In a similar manner there was obtained methyl 2-methyl-5-methoxy-1-(7-chloroquinazolin-4-yl)indol-3-ylacetate, m.p. 112—114°C., from the appropriate starting materials.

Example 18.

55 A mixture of laevisulinic acid (15g.) and acetaldehyde N^1 -(7-chloroquinazolin-4-yl)-*p*-methoxyphenylhydrazone hydrochloride (3.3g.) was heated at 95—100°C. for 18 hours. The mixture was poured into water (ca 300ml.), and the precipitated pale yellow solid was collected by filtration and dissolved in a mixture of water (80ml.) and ammonia solution (specific gravity 0.88, ca 5ml.). The solution was washed with ethyl acetate (2×25ml.). Addition of sodium chloride (ca 10g.) to the aqueous phase caused a yellow solid to precipitate. This was collected by filtration, and then dissolved in water. The solution was acidified with glacial acetic acid until precipitation was complete. The mixture was filtered to give, as solid residue, 2-methyl-5-methoxy-1-(7-chloroquinazolin-4-yl)indol-3-ylacetic acid monohydrate, m.p. 98—100°C.

60 The starting material was obtained as follows:—

To a solution of 4,7-dichloroquinazoline (2.0g.) in dry 1,2-dimethoxyethane (50ml.; dried over sodium alumino-silicate, see Example 11) was added acetaldehyde *p*-methoxyphenylhydrazone (1.6g.), and the mixture was heated under reflux for 30 minutes. The mixture was cooled to ca 25°C. and the precipitate of acetaldehyde N^1 -(7-chloroquinazolin-4-yl)-*p*-methoxyphenylhydrazone hydrochloride, m.p. 193—195°C. (decomposition), was collected by filtration.

Example 19.

65 In an analogous manner to that described in Example 4, the following compounds were prepared:—

65

70

75

80

85

90

95


100

105

110

115

120



(XXXII)

Compound number (see below)	R ¹	R ⁶	R ⁶	Characteristic Properties
(1)	quinazolin-4-yl	methoxy	dimethylamino	m.p. 142—145°C.
(2)	6-methoxy-4-methyl-quinol-2-yl	ethoxy	methoxy	NMR: —OCH ₂ at 6.1 τ; pure by TLC (on silica gel: elution with ether; petroleum ether (b.p. 40—60°C.) 1:3)*
(3)	7-methylquinol-4-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.1 τ; pure by TLC (System C)
(4)	quinoxalin-2-yl	methoxy	methoxy	m.p. 110—112°C.

*TLC system hereinafter referred to as system D.

5 The indoline derivative used as starting material in the preparation of compound (1) above, i.e. methyl 5-dimethylamino-2-methyl-1-quinazolin-4-ylindolin-3-ylacetate, was prepared as follows:—

10 A solution of methyl 1-acetyl-2-methyl-indolin-3-ylacetate (6.83 g.) in concentrated sulphuric acid (45 ml.) was cooled to 0°C. and a solution of sodium nitrate (2.67 g.) in concentrated sulphuric acid (20 ml.) was added dropwise during 0.5 hr. The mixture was stirred at 0°C. for a further 0.5 hr and then poured onto ice (300 ml.). The resulting precipitate was filtered and washed well with water. Crystallisation from methanol gave methyl 1-acetyl-2-methyl-5-nitro-indolin-3-ylacetate, m.p. 106°C.

15 A solution of this nitro derivative (12.3 g.) in methanol (400 ml.) containing 37% w/v formalin solution (7 ml.) was shaken with 10% w/w palladium on charcoal (10.5 g) in an atmosphere of hydrogen at room temperature and atmospheric pressure. The 20 hydrogen uptake was 5150 ml. After hydrogenation, the catalyst was filtered off and the filtrate evaporated *in vacuo*. The residue was crystallised from benzene to give methyl 1-acetyl-5-dimethylamino-2-methyl-1-quinazolin-4-ylindolin-3-ylacetate, as a syrup which was 25 shown to be pure by TLC (systems A and B).

30 A solution of this dimethylamino derivative (8 g.) in methanol (125 ml.) was refluxed for 1 hour whilst a stream of hydrogen chloride gas was passed through it. Anhydrous sodium acetate (5 g.) was added to the reaction mixture, and the bulk of the methanol removed *in vacuo* at 40°C.

35 The residue was dissolved in ether (50 ml.), and the solution was washed successively with saturated aqueous sodium acetate solution (20 ml.) and water (20 ml.). The ethereal solution was dried (MgSO₄) and evaporated to yield methyl 5-dimethylamino-2-methyl-indolin-3-ylacetate as an oil, shown to be pure by TLC (System C).

40 This indoline derivative was then reacted with 4-chloroquinazoline in a similar manner to that described in Example 4 for the preparation of ethyl 1-quinazolin-4-ylindolin-3-ylacetate, and there was obtained methyl 5-dimethylamino-2-methyl-1-quinazolin-4-ylindolin-3-ylacetate, as a syrup which was 45 shown to be pure by TLC (systems A and B).

50 The indoline derivatives used as starting materials in the preparation of compounds (2) and (3) in the above table were prepared in a similar manner to that described in Example 4 for ethyl 5-methoxy-2-methyl-1-(4-methyl-

35

40

45

50

55

2-phenylpyrimidin-6-yl)indolin-3-ylacetate. Both compounds had NMR —OCH₃ at 6.2 τ , and both were shown to be pure by TLC (systems A, C and D).


5 The indoline derivative used as starting material in the preparation of compound (4) in the above table was prepared as follows:—

Anhydrous sodium acetate (3.6 g.) was added to a mixture of methyl 5-methoxy-2-methylindolin-3-ylacetate (8.0 g.) and 2,3-dichloroquinoxaline (6.8 g.) in diethylene-glycol dimethyl ether (150 ml.), and the mixture was heated under reflux for 12 hrs. The mixture was then cooled and poured into water (800 ml.), and the aqueous suspension was extracted with ethyl acetate (3 \times 50 ml.). The combined extracts were washed suc-

sively with water (4 \times 30 ml.) and a saturated aqueous solution of sodium chloride (50 ml.), and then dried (MgSO₄) and evaporated. The resultant syrup was chromatographed on chromatographic silica gel (M.F.C., 300 g.) using an increasing gradient of diethyl ether in petroleum ether (b.p. 40—60°C.) (polarity increased by incremental addition of 10% v/v ether.) The combined eluate was evaporated to give methyl 1-(3-chloroquinoxalin-2-yl)-5-methoxy-2-methylindolin-3-ylacetate, m.p. 155—157°C.

Example 20.

In analogous manner to that described in Example 7, the following compounds were prepared from the appropriate methyl or ethyl ester:—




R ¹	R ⁶	Characteristic properties
6-chloroquinol-2-yl	methoxy	m.p. 193—195°C.
8-chloroquinol-4-yl	methoxy	m.p. 272—273°C. (hemihydrate)
7-bromoquinol-4-yl	methoxy	m.p. 251—253°C. (hemihydrate)
7-methoxyquinol-4-yl	methoxy	m.p. 123—125°C. (hemihydrate)
7-methylquinol-4-yl	methoxy	m.p. 268—2769°C.
6-methoxy-4-methylquinol-2-yl	methoxy	m.p. 108—110°C. (hemihydrate)
isoquinol-1-yl	methoxy	m.p. 195°C. (hemihydrate)
7-chloroquinazolin-4-yl	methyl	m.p. 115—118°C.
7-trifluoromethylquinol-4-yl	methoxy	m.p. 180—182°C.
6,7-dichloroquinol-4-yl	methoxy	m.p. 258—260°C.
6-chloro-4-phenylquinazolin-2-yl	methoxy	m.p. 98—100°C. (monohydrate)

Example 21.

In an analogous manner to that described in Example 11 the following compounds were prepared from the appropriate starting

40 materials using either 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or 2,3,5,6-tetrachloro-1,4-benzoquinone(CA):—




R ¹	R ⁷	R ⁶	Characteristic properties	Quinone used
7-chloroquinazolin-4-yl	methoxy	methyl	NMR: —CH ₃ at 7.6 τ ; pure by TLC (System A).	DDQ
6-chloroquinol-2-yl	methoxy	methoxy	m.p. 104—105°C.	DDQ
8-chloroquinol-4-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.18 τ ; pure by TLC (System C)	DDQ
7-bromoquinol-4-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.20 τ ; pure by TLC (System C)	DDQ
6-chloro-4-phenyl-quinazolin-2-yl	ethoxy	methoxy	m.p. 143—144°C.	DDQ
6,7-dichloroquinol-4-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.15 τ ; pure by TLC (Systems A and C)	DDQ
7-trifluoromethyl-quinol-4-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.20 τ ; pure by TLC (Systems A and C)	DDQ
7-methoxyquinol-4-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.18 τ ; pure by TLC (System C)	CA
isoquinol-1-yl	methoxy	methoxy	NMR: 5—OCH ₃ at 6.22 τ ; pure by TLC (Systems A and C)	CA

5 The starting material used in the preparation of the first compound in the above table, i.e. methyl 1-(7-chloroquinazolin-4-yl)-2,5-dimethylindolin-3-ylacetate, was obtained in an analogous manner to that described in Example 4 for the preparation of ethyl 1-quinazolin-4-ylindolin-3-ylacetate. The compound had NMR: —CH₃ at 7.6 τ and 10 was shown to be pure by TLC (Systems A and B).

15 The indoline derivatives used as starting materials in the preparation of all of the other compounds in the above table were prepared in analogous manner to that described in Example 4 for the preparation of ethyl 5-methoxy-2-methyl-1-(4-methyl-2-phenylpyrimidin-6-yl)indolin-3-ylacetate, and they have the following characteristic properties:—

20



R^1	R^7	Characteristic properties
6-chloroquinol-2-yl	methoxy	m.p. 128—130°C.
8-chloroquinol-4-yl	methoxy	NMR: 5—OCH ₃ at 6.20 τ ; pure by TLC (System C)
7-bromoquinol-4-yl	methoxy	NMR: 5—OCH ₃ at 6.18 τ ; pure by TLC (System C)
6-chloro-4-phenyl-quinazolin-2-yl	ethoxy	m.p. 174—175°C.
6,7-dichloroquinol-4-yl	methoxy	NMR: 5—OCH ₃ at 6.15 τ ; pure by TLC (Systems A and C)
7-trifluoromethyl-quinol-4-yl	methoxy	NMR: 5—OCH ₃ at 6.20 τ ; pure by TLC (Systems A and C)
7-methoxyquinol-4-yl	methoxy	NMR: 5—OCH ₃ at 6.17 τ ; pure by TLC (System C)
isoquinol-1-yl	methoxy	NMR: 5—OCH ₃ at 6.20 τ ; pure by TLC (System A and C)


Example 22.

In a similar manner to that described in Example 17, but starting with ethyl α -methylsuccinate *p*-methoxyphenylhydrazone, there was obtained ethyl α -[1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methyl-indol-3-yl]propionate as a viscous syrup which was pure by TLC (System C) and had NMR: —OCH₃ at 6.20 τ .

Example 23.

In a similar manner to that described in Example 18, (but the ammonium salt was not isolated in every case) the following compounds were obtained from the appropriate phenylhydrazone derivatives:—

15




R^1	R^6	Characteristic properties
7-fluoroquinazolin-4-yl	methoxy	m.p. 90—93°C. (hemihydrate)
7-bromoquinazolin-4-yl	methoxy	m.p. 104—106°C. (hemihydrate)
8-chloroquinazolin-4-yl	methoxy	m.p. 102—105°C. (hemihydrate)
7-methylquinazolin-4-yl	methoxy	m.p. 95—100°C. (monohydrate)
7-chloroquinazolin-4-yl	methyl	m.p. 115—118°C.
2-methylquinazolin-4-yl	methoxy	m.p. 97—99°C. (hemihydrate)

In a similar manner, using α -methyl-laevulinic acid and acetaldehyde N^1 -(7-chloroquinazolin-4-yl)- p -methoxyphenyl-hydrazone hydrochloride as starting materials, there was obtained α -(1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-yl)propionic acid, m.p. 110-112°C.

The following hydrazone derivatives, used as starting materials in preparing the indole derivatives described in this Example (except for the last, in respect of which see Example 18), were prepared in a similar manner to that described in Example 18:—

10



(XIV)

R^1	R^6	Characteristic properties
7-fluoroquinazolin-4-yl	methoxy	NMR: $-\text{OCH}_3$ at 6.13 τ ; pure by TLC (Systems A and D)
7-bromoquinazolin-4-yl	methoxy	m.p. 156-158°C.
8-chloroquinazolin-4-yl	methoxy	NMR: $-\text{OCH}_3$ at 6.20 τ ; pure by TLC (Systems A and C)
7-methoxyquinazolin-4-yl	methoxy	m.p. 130-132°C.
7-chloroquinazolin-4-yl	methyl	m.p. 200-205°C. (decomposition) (hydrochloride)
2-methylquinazolin-4-yl	methoxy	m.p. 190-192°C. (hydrochloride)

15

Example 24.

Methyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetate (1.7g.) in methanol (50ml.) containing 30% w/v methylamine solution (25ml.) was refluxed for 10 hours. The solvents were evaporated *in vacuo* and the residue crystallised from a 1:1 v/v mixture of benzene and cyclohexane to give 1-(7-chloroquinol-4-yl)-5-methoxy- $N,2$ -dimethylindol-3-ylacetamide, m.p. 168-169°C.

In a similar manner, from methyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetate and ammonium hydroxide solution (specific gravity 0.88) there was obtained 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetamide, m.p. 147-148°C., and from methyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetate and hydrazine hydrate solution there was obtained 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetohydrazide, m.p. 183-184°C., and from methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate and hydrazine hydrate solution, there was obtained 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetohydrazide, m.p. 164-165°C.

Example 25.

A solution of anhydrous 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid (1.9g.) in ethanol-free chloroform (30ml., dried with calcium chloride) was treated with triethylamine (0.5ml., dried over potassium hydroxide pellets) at 0°C. A solution of ethyl chloroformate (0.48ml.) in dry, ethanol-free, chloroform (10ml.) was then added, and the mixture stirred at 0°C. for 1½ hours. A solution of 2- N,N -dimethylamino-ethanol (0.56ml.) in chloroform (5ml.) was then added. The mixture was heated under reflux for 2 hours, and then added to water (100ml.). The chloroform layer was separated, washed with water, dried (MgSO_4), and evaporated. The residual oil was purified by chromatography on silica gel (150g.) in a mixture of 5% v/v methanol and 95% v/v chloroform to give, after the elution of low polarity impurities, β -(N,N -dimethylamino)ethyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate as a pale yellow oil, NMR: OCH_3 at 6.23 τ .

In a similar manner, starting with the appropriate 1-substituted indol-3-ylacetic acid and the appropriate alcohol or phenol, there were obtained:—

45

50


55

60

65

70

75




(XXIII)

R ¹	R ⁷	R ⁶	Characteristic properties
7-chloroquinazolin-4-yl	n-butoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.2τ; pure by TLC (Systems A and C)
7-chloroquinazolin-4-yl	ethoxy	methoxy	m.p. 103—105°C.
7-chloroquinazolin-4-yl	benzyloxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.23τ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	phenoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.15τ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	cyclohexyl-methoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.2τ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	phenoxy	methyl	syrup; NMR: 5—CH ₃ , 7.55τ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	phenoxy	fluoro	m.p. 122—124°C.
7-chloroquinazolin-4-yl	ethoxy	fluoro	syrup; NMR: 2—CH ₃ , 7.7τ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	methoxy	methyl	syrup; NMR: 5—CH ₃ , 7.6τ; pure by TLC (Systems A and C)
7-chlorocinnolin-4-yl	methoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.13τ; pure by TLC (System C)
quinazolin-4-yl	ethoxy	methoxy	m.p. 121—123°C.
7-chloroquinazolin-4-yl	methoxy	methoxy	m.p. 112—114°C.
7-chloroquinol-4-yl	methoxy	methoxy	m.p. 103—105°C.

Example 26.

In a similar manner to that described in Example 25, but starting with the appropriate

1-substituted-indol-3-ylacetic acid and amine, there were obtained the following amides:—



R ¹	R ⁷	Characteristic properties
7-chloroquinol-4-yl	NHMe	m.p. 168—169°C.
7-chloroquinol-4-yl	NH ₂	m.p. 147—148°C.
7-chloroquinol-4-yl	NHNH ₂	m.p. 183—184°C.
7-chloroquinazolin-4-yl	NHPh	m.p. 132—133°C.
7-chloroquinazolin-4-yl	NH ₂	m.p. 197—198°C.
7-chloroquinazolin-4-yl	NHNH ₂	m.p. 164—165°C.

Example 27.

- A mixture of phenol (0.27g.) and anhydrous 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid (1.0g.) in dry 1,2-dimethoxyethane (20ml.; dried over sodium alumino-silicate powder) was stirred at room temperature and treated with dicyclohexylcarbodiimide (0.75g.).
- 5 The mixture became opaque, and was stirred overnight at room temperature and then filtered. Evaporation of the filtrate gave a dark yellow syrup, which was purified by chromatography on silica gel (175g.), using an increasing gradient of ether in petroleum ether (b.p. 40—60°C.) (polarity increased by incremental
- 10
- 15


addition of 10% v/v ether). The major product, phenyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate, was obtained as a yellow glass (NMR: OCH₃ at 6.20 τ ; pure by TLC: systems A and D), from the petrol rich fractions. A second product, 1-[1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetyl]-1,3-dicyclohexylurea, was obtained as a pale yellow solid of m.p. 105—107°C. (NMR: OCH₃ at 6.23 τ ; pure by TLC: system C).

In a similar manner, starting with the appropriate 1-substituted indol-3-ylacetic acid and the alcohol or phenol, there were obtained:—

20

25

30




(XXIII)

R^1	R^7	R^6	Characteristic properties
7-chloroquinazolin-4-yl	<i>n</i> -butoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.2 τ ; pure by TLC (Systems A and C)
7-chloroquinazolin-4-yl	ethoxy	methoxy	m.p. 103—105°C.
7-chloroquinazolin-4-yl	benzyloxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.23 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	cyclohexylmethoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.2 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	phenoxy	methyl	syrup; NMR: 5—CH ₃ , 7.55 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	phenoxy	fluoro	m.p. 122—124°C.
7-chloroquinazolin-4-yl	ethoxy	fluoro	syrup; NMR: 2—CH ₃ , 7.7 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	methoxy	methyl	syrup; NMR: 5—CH ₃ , 7.6 τ ; pure by TLC (Systems A and C)
7-chlorocinnolin-4-yl	methoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.13 τ ; pure by TLC (System C)
quinazolin-4-yl	ethoxy	methoxy	m.p. 121—123°C.
7-chloroquinazolin-4-yl	methoxy	methoxy	m.p. 112—114°C.
7-chloroquinol-4-yl	methoxy	methoxy	m.p. 103—105°C.

Example 28.

In a similar manner to that described in Example 27 but starting with the appropriate

1-substituted-indol-3-ylacetic acid and amine, there were prepared the following amides:—



R^1	R^2	Characteristic properties
7-chloroquinol-4-yl	NHMe	m.p. 168-169°C.
7-chloroquinol-4-yl	NH ₂	m.p. 147-148°C.
7-chloroquinol-4-yl	NHNH ₂	m.p. 183-184°C.
7-chloroquinazolin-4-yl	NHPh	m.p. 132-133°C.
7-chloroquinazolin-4-yl	NH ₂	m.p. 197-198°C.
7-chloroquinazolin-4-yl	NHNH ₂	m.p. 164-165°C.

Example 29.

A solution of sodium (0.7g.) in dry methanol (30ml.; dried over sodium aluminosilicate) was added to a solution of 1-(2,6-dichloropyrimid-4-yl)-2,5-dimethylindol-3-ylacetic acid (3.5g.) in dry methanol (90ml.), and the mixture was heated under reflux for 2 hours. After removal of solvent under reduced pressure, the residue was dissolved in water (50ml.) and the solution acidified to pH 4 with acetic acid. The resulting mixture was filtered, and the solid residue crystallised from benzene to give 1-(2,6-dimethoxypyrimid-4-yl)-2,5-dimethylindol-3-ylacetic acid, m.p. 197-198°C.

In a similar manner, starting with the appropriate 1-(2,6-dichloropyrimid-4-yl)indol-3-ylacetic acid, there were obtained 1-(2,6-dimethoxypyrimid-4-yl)-2-methylindol-3-ylacetic acid, m.p. 122-123°C., and 1-(2,6-dimethoxypyrimid-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid, m.p. 155-158°C.

Example 30.

Methyl 1-(7-chloroquinol-4-yl)-5-methoxy-2-methylindol-3-ylacetate (1g.) and sodium borohydride (1g.) in methanol (30ml.) were refluxed for 1 hour. Most of the methanol was then removed *in vacuo*, and the residue was diluted with water (50ml.), and extracted with ethyl acetate (3×50ml.). The combined extracts were dried ($MgSO_4$) and evaporated to give an oil, which was chromatographed on silica gel (100g.) using, as eluant, petroleum ether (b.p. 40-60°C.) containing an increasing proportion of ether (polarity increased by incremental addition of 10% v/v ether) to give

1-(7-chloroquinol-4-yl)-3-(2-hydroxyethyl)-5-methoxy-2-methylindole, m.p. 143-145°C.

Similarly, from methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate, there was obtained 1-(7-chloroquinazolin-4-yl)-3-(2-hydroxyethyl)-5-methoxy-2-methylindole, m.p. 148-150°C., and from methyl 1-(7-chloroquinazolin-4-yl)-2,5-dimethylindol-3-ylacetate, there was obtained 1-(7-chloroquinazolin-4-yl)-2,5-dimethyl-3-(2-hydroxyethyl)indole as a glass [pure by TLC (system A) and having a satisfactory NMR spectrum ($-CH_3$ at 7.6 τ and $-CH_3$ at 7.7 τ)].

Example 31.

A solution of 1-(7-chloroquinazolin-4-yl)-2,5-dimethylindol-3-ylacetic acid (1.8g.) in dimethylformamide (30ml.; dried by distillation from calcium hydride) was added to sodium hydride (0.13g.), and the mixture was stirred under a slight vacuum (*ca* 150mm. Hg) until complete dissolution occurred. Methyl iodide (2ml.) was then added, and the mixture was stirred for 2 hours at 40-50°C. The mixture was then added to water (200ml.) and the resulting mixture extracted with ethyl acetate (3×50ml.). The combined extracts were washed successively with saturated sodium bicarbonate solution (3×30ml.), water and brine (50ml.). After drying ($MgSO_4$), the extracts were evaporated *in vacuo* to give methyl 1-(7-chloroquinazolin-4-yl)-2,5-dimethylindol-3-ylacetic acetate as a stiff syrup [NMR: 5- CH_3 at 7.6 τ ; pure by TLC (system A)].

In a similar manner, starting with the appropriate alkyl halide, there were obtained:

40

50

55


60

65

70

75

80



(XIII)

R^1	R^7	R^6	Characteristic properties
7-chloroquinazolin-4-yl	<i>n</i> -butoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.2 τ ; pure by TLC (Systems A and C)
7-chloroquinazolin-4-yl	ethoxy	methoxy	m.p. 103—105°C.
7-chloroquinazolin-4-yl	benzyloxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.23 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	cyclohexylmethoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.2 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	ethoxy	fluoro	syrup; NMR: 2—CH ₃ ; pure by TLC (Systems A and D)
7-chlorocinnolin-4-yl	methoxy	methoxy	syrup; NMR: 5—OCH ₃ , 6.13 τ ; pure by TLC (System C)
quinazolin-4-yl	ethoxy	methoxy	m.p. 121—123°C.
7-chloroquinazolin-4-yl	methoxy	methoxy	m.p. 112—114°C.

Example 32.

5 A solution of acetaldehyde N^1 -(7-chloroquinazolin-4-yl)-*p*-methoxyphenylhydrazone hydrochloride (3.2g.) and 5-hydroxypentan-2-one (1.1g.) in ethanol (60ml.) was refluxed for 18 hours. The mixture was cooled and filtered and the filtrate evaporated *in vacuo*. The residue was 10 chromatographed on silica gel (100g.) using, as eluant, petroleum ether (b.p. 40—60°C.) containing an increasing proportion of ether (polarity increased by incremental addition of 10% v/v ether) to give 1-(7-chloroquinazolin-4-yl)-3-(2-hydroxyethyl)-5-methoxy-2-methylindole, m.p. 148—150°C.

15 Similarly, from acetaldehyde N^1 -(7-chloroquinazolin-4-yl)-*p*-methylphenylhydrazone hydrochloride and 5-hydroxypentan-2-one, there was obtained 1-(7-chloroquinazolin-4-yl)-2,5-dimethyl-

3-(2-hydroxyethyl)indole as a glass [pure by TLC (system C) and having a satisfactory NMR spectrum ($—CH_3$ τ 7.60 and $—CH_3$ τ 7.70)].

25

Example 33.

20 A solution of 1-(7-chloroquinazolin-4-yl)-3-(2-hydroxyethyl)-5-methoxy-2-methylindole (0.6g.) and acetic anhydride (0.4g.) in benzene (20ml.; dried over sodium wire) was refluxed for 15 hours. The resulting yellow solution was cooled and washed successively with saturated sodium hydrogen carbonate solution (2 \times 20ml.) and water (20ml.), and dried ($MgSO_4$). The solution was evaporated to give 2-[1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-yl]ethyl acetate as an oil [pure by TLC (system A) and having a satisfactory NMR spectrum ($—OCH_3$ τ 6.18)].

30

35

40

Example 34.

A solution of ethyl 1-(7-chloroquinazolin-4-yl)-5-hydroxy-2-methylindol-3-ylacetate (1.0g.) in dry dimethylformamide (10ml.); dried by distillation from calcium hydride, and stored over sodium aluminosilicate was added to sodium hydride (0.068g.), and the mixture was stirred under a slight vacuum (*ca* 150mm. Hg) at room temperature for 15 minutes. n-Propyl iodide (0.9g.) was added to the resulting clear solution, and the mixture stirred at room temperature overnight. The solution was added to water (300ml.) and extracted with ethyl acetate (3×40ml.). The combined extracts were washed with a saturated solution of sodium chloride (30ml.), dried ($MgSO_4$), and then evaporated *in vacuo*. The yellow oil thus obtained was treated with tetrachloroethylene (100ml.) and the solution evaporated *in vacuo*. This process was then repeated with ethanol (50ml.) to give ethyl 1-(7-chloroquinazolin-4-yl)-2-methyl-5-n-propoxyindol-3-ylacetate as a stiff yellow syrup [NMR: 2-CH₃ at 7.65 τ ; pure by TLC (systems A and D)].

In a similar manner, but using methyl iodide, there was obtained ethyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate as a yellow solid, m.p. 103-105°C. [NMR: 5-OCH₃ at 6.2 τ ; pure by TLC (systems A and C)].

The 5-hydroxyindole derivative used as starting material was obtained as follows:—

A solution of ethyl 5-benzyloxy-1-(7-chloroquinazolin-4-yl)-2-methylindol-3-ylacetate (1.5g.) in glacial acetic acid (5ml.) was treated with a 50% w/v solution of hydrogen bromide in glacial acetic acid (5ml.). The resulting dark red solution was stirred at room temperature for 10 minutes and then neutralised by the addition to a mixture of saturated sodium acetate solution (50ml.) and water (150ml.). The mixture was extracted with ethyl acetate (3×50ml.) and the extracts washed successively with water (2×40ml.), saturated sodium hydrogen carbonate solution (2×40ml.), water (40ml.) and then saturated sodium chloride solution (40ml.). After drying ($MgSO_4$), the extracts gave on evaporation *in vacuo* a yellow-brown oil. Purification by chromatography on silica gel (200g.) in a

mixture of 50% v/v ether and 50% v/v petroleum ether (b.p. 40-60°C.), gave ethyl 1-(7-chloroquinazolin-4-yl)-5-hydroxy-2-methylindol-3-ylacetate as a pale yellow glass [NMR: 2-CH₃ at 7.7 τ ; pure by TLC (systems A, C and D)].

The ethyl 5-benzyloxy-1-(7-chloroquinazolin-4-yl)-2-methylindol-3-ylacetate used as starting material was obtained as a yellow syrup [NMR: 5-OCH₂ at 6.25 τ ; pure by TLC (systems A and C)] from the corresponding acetic acid in an analogous manner to that described in Example 31.

The 5-benzyloxy-1-(7-chloroquinazolin-4-yl)-2-methylindol-3-ylacetic acid used as starting material was obtained as a yellow solid, m.p. 97-99°C. (decomposition) from acetaldehyde *N*¹-(7-chloroquinazolin-4-yl)-*p*-benzyloxyphenylhydrazone hydrochloride by an analogous procedure to that described in Example 18.

Example 35.

A mixture of acetaldehyde *N*¹-(7-chloroquinazolin-4-yl)-*p*-methoxyphenylhydrazone hydrochloride (25g.) and laevulinic acid (50g.) in acetic acid (120ml.) was heated under reflux for 1-2 hours. The dark red mixture was then added to water (1.5 l.). The solid obtained was separated by filtration and dissolved in a mixture of water (50ml.) and 5N-aqueous ammonium hydroxide solution (50ml.). The solution was extracted with ether (3×50ml.) and the aqueous layer acidified with acetic acid to pH 4. The mixture was then extracted with ethyl acetate (3×50ml.) and the extracts washed with water (30ml.) and then with saturated sodium chloride solution (30ml.) before being dried ($MgSO_4$). Evaporation of the solvent gave a dark brown syrup which crystallised on addition of methanol (40ml.) to give 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid as a yellow solid, m.p. 205-208°C.

Example 36.

In a similar manner to that described in Example 18, (but the ammonium salt was not isolated in every case) the following compounds were obtained from the appropriate substituted phenylhydrazone:—

75


80

85

90

95

100



R^1	R^6	Characteristic properties
7-chloroquinazolin-4-yl	5—OEt	m.p. 120°C. ($\frac{1}{2}$ H ₂ O)
7-chloroquinazolin-4-yl	5—Et	m.p. 108—109°C. ($\frac{1}{2}$ H ₂ O)
6,8-dibromoquinazolin-4-yl	5—OMe	m.p. 123—130°C. (H ₂ O)
7-chloro-2-methyl-quinazolin-4-yl	5—OMe	m.p. 103—108°C. ($\frac{1}{2}$ H ₂ O)
7-chloroquinazolin-4-yl	5-t-Bu	m.p. 120—122°C.
quinazolin-4-yl	5-methyl	m.p. 212—216°C.
7-chloroquinazolin-4-yl	5,6-ethylenedioxy	m.p. 128—130°C.
7-chloroquinazolin-4-yl	4,6-dimethyl	m.p. 117°C.
7-chloroquinazolin-4-yl	mixture of 4- and 6—OMe	m.p. 94—98°C.
7-chloroquinazolin-4-yl	mixture of 4,5- and 5,6-diMe	m.p. 114—118°C.
7-chloroquinazolin-4-yl	5—Br	m.p. 95—100°C. ($\frac{1}{2}$ H ₂ O)
5,7-dichloroquinazolin-4-yl	5—OMe	m.p. 130—135°C.
7-chloroquinazolin-4-yl	5—F	m.p. 99—100°C. (H ₂ O)
7-chloroquinazolin-4-yl	5,6-methylenedioxy	m.p. 105—108°C. (H ₂ O)
7-chloroquinazolin-4-yl	5—Cl	m.p. 213—217°C.
2-methylquinazolin-4-yl	5—F	pure by TLC (System E*) NMR: 2—CH ₃ at 7.80 τ .
2-isopropylquinazolin-4-yl	5—OMe	pure by TLC (Systems A, C and E); NMR: 2-i-Pr at 8.60 and 8.68 τ .
2-methylquinazolin-4-yl	5—Me	m.p. 95—100°C. (H ₂ O)
2-ethylquinazolin-4-yl	5—OMe	pure by TLC (Systems C and E); NMR: —OCH ₃ at 6.18 τ .


*Chloroform 95 parts, methanol 4 parts, formic acid 1 part on silica gel; hereinafter referred to as System E.

In an analogous manner there were obtained α - [1 - (7 - chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - yl] isobutyric acid, m.p. 105 - 107°C., and α - [1 - (7 - chloroquinazolin - 4 - yl) - 2,5 - dimethylindol - 3 - yl] propionic acid, m.p. 98 - 102°C. (mono-

hydrate), from the appropriate starting materials.

The following hydrazone derivatives, which were used as starting materials in this Example, were prepared in a similar manner to that described in Example 18: —

10



R ¹	R ⁶	Characteristic properties
7-chloroquinazolin-4-yl	4—OEt	m.p. 192—194°C. (dec.) (hydrochloride)
7-chloroquinazolin-4-yl	4—Et	m.p. 190—191°C. (dec.) (hydrochloride)
6,8-dibromoquinazolin-4-yl	4—OMe	m.p. 113—115°C. (dec.) (hydrochloride)
7-chloro-2-methyl-quinazolin-4-yl	4—OMe	m.p. 174—175°C. (dec.) (hydrochloride)
7-chloroquinazolin-4-yl	4—t-Bu	pure by TLC (Systems A and C); NMR: t-Bu at 8.65 τ
7-chloroquinazolin-4-yl	3,4-ethylenedioxy	m.p. 203—206°C. (dec.) (hydrochloride)
7-chloroquinazolin-4-yl	3,5-dimethyl	glass; NMR: 3,5-di-CH ₃ at 7.55 τ ; pure by TLC (System C)
7-chloroquinazolin-4-yl	3—OMe	m.p. 97—101°C.
7-chloroquinazolin-4-yl	3,4-dimethyl	m.p. 205—206°C. (dec.) (hydrochloride)
7-chloroquinazolin-4-yl	4—Br	m.p. 175—178°C. (dec.)
5,7-dichloroquinazolin-4-yl	4—OMe	glass; NMR: —OCH ₃ at 6.2 τ ; pure by TLC (Systems A and D)
7-chloroquinazolin-4-yl	4—F	m.p. 198—200°C. (dec.) (hydrochloride)
7-chloroquinazolin-4-yl	3,4-methylenedioxy	m.p. 209—210°C. (dec.) (hydrochloride)
7-chloroquinazolin-4-yl	4—Cl	m.p. 200—206°C. (dec.) (hydrochloride)

R¹	R⁶	Characteristic properties
2-methylquinazolin-4-yl	4-F	syrup; NMR: —CH ₃ at 7.2 τ ; pure by TLC (Systems A and C)
2-isopropylquinazolin-4-yl	4-OMe	syrup; NMR: —CH ₃ , doublet at 8.9 τ ; pure by TLC (Systems A and D)
2-methylquinazolin-4-yl	4-Me	syrup; NMR: 4—CH ₃ at 7.8 τ ; pure by TLC (System A)
2-ethylquinazolin-4-yl	4-OMe	syrup; NMR: —OCH ₃ at 6.1 τ ; pure by TLC (Systems A and C)
quinazolin-4-yl	4-Me	syrup; NMR: 4—CH ₃ at 7.85 τ ; pure by TLC (Systems A and C)

Example 37.

A solution of methyl 1-(7-aminoquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate (0.5g.) in acetic acid (12 ml.) was treated with concentrated hydrochloric acid (1.5 ml.). The solution obtained was stirred at 0-5°C during the addition, over 15 minutes, of a solution of sodium nitrite (0.15g.) in water (2 ml.). The dark red solution was added dropwise to a solution of cuprous chloride (0.2g.) in concentrated hydrochloric acid (5ml.) kept at room temperature. The mixture was then stirred for 1 hr. before addition of sufficient sodium acetate to adjust the pH of the mixture to 4-5. The mixture was then concentrated *in vacuo* and the residue treated with water (100ml.) and ethyl acetate (50ml.). The aqueous layer was extracted with ethyl acetate (2×30ml.) and the extracts washed with saturated sodium hydrogen carbonate solution (2×30ml.). After being washed with water (30ml.) and dried (Na₂SO₄), evaporation of the extracts *in vacuo* gave an oil, which slowly solidified to give methyl 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methyl-indol-3-ylacetate as a yellow solid, m.p. 111-114°C.

The amino-derivative used as starting material was obtained as follows:—

A solution of methyl 5-methoxy-2-methyl-1-(7-nitroquinazolin-4-yl)indol-3-ylacetate (2.0g.) in ethanol (80ml.; dried over sodium aluminosilicate) was treated with palladised charcoal (0.5g.; 10% w/w) and the mixture hydrogenated at atmospheric pressure. After the uptake of the theoretical amount of hydrogen, the catalyst was separated by filtration through a Celite pad.

Evaporation of the ethanol gave a red syrup which was purified by chromatography on silica gel (150g.). The less polar by-products were removed by elution with ether. Elution with methanol then gave methyl 1-(7-aminoquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetate as an orange glass having a satisfactory NMR spectrum (5—OCH₃ at 6.15 τ) and shown to be pure by TLC (system C).

The methyl 5-methoxy-2-methyl-1-(7-nitroquinazolin-4-yl)indol-3-ylacetate used as starting material was obtained as a red solid, m.p. 179-181°C., from the corresponding indoline derivative as described in Example 11. Methyl 5-methoxy-2-methyl-1-(7-nitroquinazolin-4-yl)-indolin-3-ylacetate was obtained as a red glass [NMR: 5—OCH₃ at 6.15 τ ; pure by TLC (systems A and C)] in a similar manner to that described in Example 4 for the preparation of ethyl 1-quinazolin-4-ylindolin-3-ylacetate.

Example 38.

In an analogous manner to that described in Example 16, there was obtained methyl 1-(benzoxazol-2-yl)-5-methoxy-2-methylindol-3-ylacetate, m.p. 125-126°C., from the appropriate starting materials.

Example 39.

In a similar manner to that described in Example 18, 1-(7-chloroquinazolin-4-yl)-5-methoxy-2-methylindol-3-ylacetic acid was prepared from acetone *N*¹-(7-chloroquinazolin-4-yl)-*p*-methoxyphenylhydrazone hydrochloride and laevulinic acid, and it was also prepared from benzaldehyde

40

50

55

60

65

70

75

80


N^1 - (7 - chloroquinazolin - 4 - yl) - p - methoxyphenylhydrazone hydrochloride and levulinic acid.

The starting materials were obtained as 5 described in Example 18 for acetaldehyde N^1 - (7 - chloroquinazolin - 4 - yl) - p - methoxyphenylhydrazone hydrochloride. Thus, from acetone - p - methoxyphenylhydrazone and 10 4,7-dichloroquinazoline, there was obtained acetone N^1 - (7 - chloroquinazolin - 4 - yl) - p - methoxyphenylhydrazone hydrochloride [this compound was unstable; the free base was shown to be pure by TLC (system C) when first isolated, but it decomposed on keeping] 15 and from benzaldehyde p -methoxyphenylhydrazone and 4,7-dichloroquinazoline, there was obtained benzaldehyde N^1 - (7-chloroquinazolin - 4 - yl) - p - methoxyphenylhydrazone hydrochloride, m.p. 227-228°C.

20 Example 40.
A mixture of 1-(7-chloroquinazolin-4-yl)- p -

methoxyphenylhydrazine (2.0g.) and levulinic acid (8.0g.) was heated at 90-95°C for 4hrs. The dark red mixture was poured into water. The yellow precipitate was collected by filtration, dissolved in a mixture of 2N-aqueous ammonia solution (25ml.) and water (25ml.) and filtered. The filtrate was washed with ether (2×30ml.), and the aqueous layer acidified with acetic acid to pH 4 to give 1-(7-chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - 25 methylindol-3-ylacetic acid hemi-hydrate, m.p. 94-96°C. (dec.). The hemi-hydrate (1.8g.) was dissolved in ethyl acetate (50ml.), and the solution dried ($MgSO_4$) and evaporated *in vacuo*. The resulting yellow glass was treated with methanol (10ml.) to give anhydrous 1 - (7 - chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - 30 methylindol - 3 - 35 ylactic acid, m.p. 206-208°C.

40 In a similar manner, but starting with the appropriate oxo-compound, there were obtained the following derivatives:—



R^1	R^3	R^4	R^5	m.p.
7-chloroquinazolin-4-yl	H	H	CO_2Me	112-114°C
7-chloroquinazolin-4-yl	H	H	CH_2OH	148-150°C
7-chloroquinazolin-4-yl	Me	H	CO_2H	110-112°C
7-chloroquinazolin-4-yl	Me	Me	CO_2H	105-107°C
7-chloroquinazolin-4-yl	H	H	$CONH_2$	197-198°C

45 The starting material was obtained by the following two methods:—

i) A solution of 4,7-dichloroquinazoline (1.0g.) and p -methoxyphenylhydrazine (0.7g.) in 1,2-dimethoxyethane (25ml.; dried over sodium 50 alumino-silicate) was heated under reflux for 1 hr. The resulting red mixture was concentrated *in vacuo* to give a sticky residue, to which was added water (50ml.) and ethyl acetate (50ml.). The aqueous layer was 55 extracted with ethyl acetate (2×30ml.). The combined extracts were washed with water, dried (Na_2SO_4) and evaporated *in vacuo*. The resultant red syrup was purified by chromatography on silica (MFC, 130g.) in an increasing gradient of ether in petroleum ether (b.p.

40-60°C.) (polarity increased by incremental addition of 20% v/v ether), to give from the ether rich fractions, N^1 -(7-chloroquinazolin-4-yl)- p -methoxyphenylhydrazine, as a yellow solid, m.p. 125-127°C.

65 ii) A suspension of acetaldehyde N^1 -(7-chloroquinazolin - 4 - yl) - p - methoxyphenylhydrazone hydrochloride (15.0g.) in ethanol (120ml.; dried over magnesium ethoxide) was cooled and stirred at 5-10°C for 3 hrs. during the passage of dry hydrogen chloride. The mixture was then left at 0-5°C. for 3 days before separation by filtration. The solid was washed with dry ether (10ml.), and then dissolved in a mixture of water (30ml.), saturated sodium acetate solution (5ml.) and

65

70

75

ethyl acetate (25ml.). The aqueous layer was extracted with more ethyl acetate (2×15ml.), and the extracts washed with water (20ml.), dried (Na_2SO_4) and evaporated to give N^1 - (7 - chloroquinazolin - 4 - yl) - *p* - methoxyphenylhydrazine, m.p. 124—127°C.

Example 41.

In an analogous manner to that described in Example 11 there was obtained methyl 1- (2 - methoxyquinazolin - 4 - yl) - 5 - methoxy-2-methylindol-3-ylacetate, m.p. 152—154°C., from the appropriate starting material.

The starting material was prepared as follows:—

A mixture of 2,4-dichloroquinazoline (3.2g.), ethyl 5-methoxy-2-methylindolin-3-ylacetate (4.0g.) and triethylamine (2.23ml.; dried over potassium hydroxide pellets) in dry 1,2-dimethoxyethane (50ml.) was heated under reflux for 30 mins. The mixture was evaporated *in vacuo*, and to the residue was added water (100ml.) and ethyl acetate (50ml.). The aqueous layer was separated and extracted with ethyl acetate (2×30ml.), and the extracts were washed with water (30ml.), dried (MgSO_4) and evaporated. The residual syrup slowly crystallised to give ethyl 1-(2-chloroquinazolin - 4 - yl) - 5 - methoxy - 2-methylindolin-3-ylacetate, m.p. 111—112°C. This indoline ester (3.6g.) was added to a solution of sodium (0.5g.) in methanol (50ml.; dried over magnesium methoxide), and the resulting solution was heated under reflux for 18 hrs. After removal of methanol *in vacuo*, the mixture was added to water (50ml.) and acidified with acetic acid to give 1-(2-methoxyquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindolin-3-ylacetic acid hemihydrate, m.p. 115—120°C. This acid (3.0g.) was dissolved in dry methanol (40ml.) containing concentrated sulphuric acid (0.1ml.), and the mixture was heated under reflux for 5 hrs. Saturated sodium acetate solution (2ml.) was added, and the mixture was evaporated *in vacuo*. The residue was partitioned between water (50ml.) and ether (40ml.). After separation, the aqueous layer was extracted with ether (2×20ml.). The ether extracts were washed successively with saturated sodium hydrogen carbonate solution (20ml.) and water (20ml.), dried (Na_2SO_4), and evaporated to give methyl 1 - (2 - methoxyquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindolin - 3 - ylacetate as a dark yellow syrup [pure by TLC (system A); NMR: 5— OCH_3 at 6.3 τ ; 2— OCH_3 at 6.15 τ].

Example 42.

To a solution of 1-(7-chloroquinazolin-4-yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetic acid (1.0g.) in dry methanol (50ml.) was added freshly distilled boron trifluoride etherate (0.5ml.), and the dark red solution was heated under reflux for 30 mins. To the solution was added saturated sodium acetate

solution (5ml.), and the mixture was concentrated *in vacuo*. The residual mixture was shaken with a mixture of water (50ml.) and chloroform (30ml.). The aqueous layer was separated and extracted with further chloroform (2×20 ml.), and the combined extracts were washed successively with saturated sodium hydrogen carbonate solution (2×20ml.), water (10ml.) and saturated sodium chloride solution (15ml.). After drying, the extracts were evaporated to give methyl 1 - (7 - chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate, m.p. 111—113°C.

In a similar manner, but starting with butan-1-ol, there was obtained n-butyl 1-(7-chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol-3-ylacetate, as a yellow syrup [pure by TLC (systems A and C); NMR: 5— OCH_3 at 6.2 τ]. Ethyl 1-(7-chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol-3-ylacetate was obtained similarly as a pale yellow solid, m.p. 103—105°C.

Example 43.

To a solution of anhydrous 1-(7-chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol-3-ylacetic acid (1.0g.) in ethanol-free chloroform (30 ml.; dried over calcium chloride) was added a solution of thionyl chloride (0.19 ml.) in chloroform (2ml.). The resulting dark red solution was stirred at room temperature for 30 mins., and then methanol (20 ml.) was added. The mixture was heated under reflux for 30 mins., saturated sodium acetate solution (2 ml.) was added, and the mixture was concentrated *in vacuo*. Water (30 ml.) was added to the residue and the mixture was extracted with ether (3×30 ml.). The ether extracts were washed successively with saturated sodium hydrogen carbonate solution (30 ml.) and water (30 ml.), and dried (Na_2SO_4). Evaporation of the solvent gave a dark yellow oil, which slowly crystallised to give methyl 1-(7-chloroquinazolin-4-yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate, m.p. 112—114°C.

In a similar manner, but using ethanol, there was obtained ethyl 1-(7-chloroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol-3-ylacetate as a thick syrup of satisfactory purity by TLC (systems A and C) and by NMR (OCH_3 at 6.2 τ). This slowly crystallised to give a yellow solid of m.p. 103—105°C.

Example 44.

A solution of 1-(7-chloroquinazolin-4-yl)-5-methoxy - 2 - methylindol - 3 - ylacetate (1.0 g.) in ammonia solution (1 ml.; specific gravity 0.88) and carbon dioxide-free water (20 ml.) was evaporated to dryness *in vacuo* to give the corresponding ammonium salt as a yellow amorphous solid.

The ammonium salt was dissolved in carbon

65

70

75

80

85

90

95

100

105

110

115

120

125


- dioxide-free water (10 ml.), and to the resulting clear yellow solution was added a solution of aluminium nitrate monohydrate (0.33g.) in water (10 ml.). The yellow precipitate which formed was separated by filtration, washed with water (10ml.), and dried over phosphorus pentoxide *in vacuo* to give aluminium 1-(7-chloroquinazolin - 4 - yl) - 5 - methoxy - 2-methylindol-3-ylacetate monohydrate, as a yellow solid of m.p. 204-208°C. (dec.).
- In a similar manner there were obtained the calcium salt [$\frac{1}{2}$ H₂O; m.p. 203-205°C. (dec.)] and the magnesium salt [$\frac{1}{2}$ H₂O; m.p. 198-201°C. (dec.)] from calcium chloride and magnesium sulphate respectively.

Example 45.

- 1 - (7 - chloroquinol - 4 - yl) - 5 - methoxy-2-methylindol-3-ylacetic acid (200 g.) was thoroughly mixed with lactose (400 g.) and 20 10% w/v aqueous gelatin solution (9 g.), and the mixture was then granulated. Maize starch (35 g.) was mixed with the granules, followed by magnesium stearate (6 g.), and the mixture was compressed into tablets containing 50,100 or 200 mg. of the active ingredient.

WHAT WE CLAIM IS:—

1. A compound of the formula:—



- wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, 30 cinnolinyl, quinazolinyl, quinoxalinyl, benz-thiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy, C₁₋₅-alkylthio, amino, halogen, trifluoromethyl, 35 chloromethyl and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR', wherein R' stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, amino or hydrazino radical; and R⁶ stands for hydrogen or not more than two substituents selected from C₁₋₅-alkoxy and C₁₋₅-alkyl radicals and halogen atoms; or a pharmaceutically-acceptable salt thereof.
- 45
2. A compound of the formula I, wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benz-thiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy; amino, halogen and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR', wherein R' stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, amino or hydrazino radical; and R⁶ stands for hydrogen or not more than two substituents selected from C₁₋₅-alkoxy and C₁₋₅-alkyl radicals and halogen atoms; or a pharmaceutically-acceptable salt thereof.
- 50
3. A compound of the formula I, wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benz-thiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy; amino, halogen and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR', wherein R' stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, amino or hydrazino radical; and R⁶ stands for hydrogen or not more than two substituents selected from C₁₋₅-alkoxy and C₁₋₅-alkyl radicals and halogen atoms; or a pharmaceutically-acceptable salt thereof.
- 55
4. A compound of the formula I, wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benz-thiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy, C₁₋₅-alkylthio, amino, halogen, trifluoromethyl and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical;


than 5 carbon atoms, and di-C₁₋₅-alkylamino radicals and halogen atoms; or a pharmaceutically-acceptable salt thereof.

2. A compound of the formula I, wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, cinnolinyl, quinazolinyl and benzthiazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy, amino, halogen and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR', wherein R' stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, amino or hydrazino radical; and R⁶ stands for hydrogen or a methoxy radical; or a pharmaceutically-acceptable salt thereof.

3. A compound of the formula I, wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benz-thiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy; amino, halogen and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical; and R³ and R⁴, which may be the same or different, stand for hydrogen or a methyl radical; and R⁵ stands for a radical of the formula —COR', wherein R' stands for a hydroxy, C₁₋₅-alkoxy, benzyloxy, phenoxy, amino or hydrazino radical; and R⁶ stands for hydrogen or not more than two substituents selected from C₁₋₅-alkoxy and C₁₋₅-alkyl radicals and halogen atoms; or a pharmaceutically-acceptable salt thereof.


4. A compound of the formula I, wherein R¹ stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benz-thiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy; amino, halogen and phenyl substituents; and R² stands for hydrogen or a C₁₋₃-alkyl radical;

- and R^3 and R^4 , which may be the same or different, stand for hydrogen or a methyl radical, and R^5 stands for a radical of the formula $—COR'$, wherein R' stands for a hydroxy, C_{1-5} -alkoxy, benzyloxy, phenoxy, di- C_{1-5} -alkylamino - C_{1-5} -alkoxy, amino, C_{1-5} -alkylamino, di- C_{1-5} -alkylamino or hydrazino radical; and R^6 stands for hydrogen or not more than two substituents selected from C_{1-5} -alkoxy, C_{1-5} -alkyl, cycloalkyl of not more than 5 carbon atoms, and di- C_{1-5} -alkylamino radicals and halogen atoms; or a pharmaceutically-acceptable salt thereof.
5. A compound as claimed in any of claims 1 to 4 which is an optically active compound possessing anti-inflammatory, analgesic and/or antipyretic activity.
6. A compound as claimed in claim 1 wherein R^2 stands for a heterocyclic radical selected from pyrimidinyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzthiazolyl and benzoxazolyl radicals, the said heterocyclic radical being linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in the said heterocyclic radical, and the said heterocyclic radical optionally bearing not more than two substituents selected from methyl, ethyl, isopropyl, methoxy, methylthio, amino, fluoro, chloro, bromo, trifluoromethyl, trichloromethyl and phenyl substituents; and R^2 , R^3 and R^4 , which may be the same or different, stand for hydrogen or a methyl radical; and R^5 stands for a radical of the formula $—COR'$ or $—CH_2OR'$, wherein R' stands for a hydroxy, methoxy, ethoxy, propoxy, butoxy, 2-dimethylaminoethoxy, benzyloxy, phenoxy, cyclohexylmethoxy, amino, methylamino, dimethylamino, anilino, hydrazino or N -1,3-dicyclohexylureido radical, and R^6 stands for hydrogen or a formyl, acetyl or propionyl radical; and R^6 stands for hydrogen or a methylenedioxy or ethylenedioxy radical or not more than two substituents selected from methoxy, ethoxy, propoxy, methyl, ethyl, propyl, butyl and dimethylamino radicals and fluorine, chlorine and bromine atoms; or a pharmaceutically-acceptable salt thereof.
10. A salt as claimed in any of claims 1 to 6 which is a pharmaceutically-acceptable acid-addition salt.
11. A salt as claimed in any of claims 1 to 6, in which the anion is derived from a said compound of the formula I wherein R^5 stands for a carboxy radical and the cation is a pharmaceutically-acceptable cation.
12. A compound as claimed in claim 2 which is 1 - (7 - chloroquinol - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate acid or a pharmaceutically-acceptable salt thereof.
13. A compound as claimed in claim 4 which is 1 - (7 - bromoquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate, or a pharmaceutically-acceptable salt thereof.
14. A compound as claimed in claim 4 which is 1 - (7 - fluoroquinazolin - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate acid, 5 - methoxy - 2 - methylindol - 3 - ylacetate, or 1 - (7 - chloroquinazolin - 4 - yl) - 2,5 - dimethylindol - 3 - ylacetate acid, or a pharmaceutically-acceptable salt thereof.
15. A compound as claimed in any of claims 1 to 4 which is an optically active compound possessing anti-inflammatory, analgesic and/or antipyretic activity.
16. A compound as claimed in claim 1 which is 1 - (2,6 - dimethoxypyrimidin - 4 - yl) - 2,5 - dimethylindol - 3 - ylacetate acid, 1 - (7 - chloroquinazolin - 4 - yl) - 5 - fluoro - 2 - methylindol - 3 - ylacetate acid or methyl 1 - (7 - chloroquinol - 4 - yl) - 5 - methoxy - 2 - methylindol - 3 - ylacetate, or a pharmaceutically-acceptable salt thereof.
17. A process for the manufacture of the compounds of the formula I, wherein R^1 , R^2 , R^3 , R^4 and R^6 have the meanings stated in claim 1 except that R' cannot stand for a hydrazino radical, and pharmaceutically-acceptable salts thereof, which comprises reacting a compound of the formula:



95

wherein R^1 and R^6 have the meanings stated above and Q stands for an amino radical or a radical of the formula:





wherein R^9 stands for hydrogen or a methyl or ethyl radical, and R^{10} stands for a methyl, ethyl or phenyl radical, or an acid-addition salt thereof, with a compound of the formula:




wherein R^2 , R^3 , R^4 and R^5 have the meanings stated above, under the influence of heat.

18. A process for the manufacture of the compounds of the formula I, wherein R^1 , R^2 , R^3 , R^4 and R^6 have the meanings stated in claim 1 and R^5 stands for a carboxy radical, and pharmaceutically-acceptable salts thereof, which comprises hydrolysing the corresponding compound of the formula:



wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated above and R¹¹ stands for a cyano, carbamoyl, alkoxy carbonyl, benzyloxy carbonyl or phenoxy carbonyl radical.

- 5 15. A process for the manufacture of the compounds of the formula I, wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated in claim 1 and R⁵ stands for a radical of the formula —COR⁷ or —CH₂OR⁸, wherein R⁷ has the meaning stated in claim 1 and R⁸ stands for a C₂₋₆-alkanoyl radical, and pharmaceutically-acceptable salts thereof, which comprises dehydrogenating, as defined hereinbefore, the corresponding indoline derivative of the formula:—




wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings stated above.


- 20 16. A process for the manufacture of the compounds of the formula I, wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated in claim 1, and R⁵ stands for a radical of the formula —COR⁷ wherein R⁷ stands for a C₁₋₅-alkoxy, benzyloxy, di-C₁₋₅-alkoxy or (C₃₋₆-cycloalkyl)methoxy radical, and pharmaceutically-acceptable salts thereof, which comprises esterifying the corresponding carboxylic acid of the formula I wherein R⁶

25 30 stands for a carboxy radical, or a salt, acid halide or anhydride thereof.

- 35 17. A process for the manufacture of the compounds of the formula I, wherein R¹ stands for a quinazolinyl, cinnolinyl, benzoxazolyl or benzthiazolyl radical, which is linked to the nitrogen atom of the indole nucleus through a ring carbon atom which is conjugated with a ring nitrogen atom in said radical, and which optionally bears not more than two substituents selected from C₁₋₅-alkyl, C₁₋₅-alkoxy, C₁₋₅-alkylthio, amino, halogen, trifluoromethyl, trichloromethyl and phenyl substituents, and R⁶ stands for a radical of the formula —COR⁷ or —CH₂OR⁸, wherein R⁷ stands for a C₁₋₅-alkoxy, benzyloxy, phenoxy, di-C₁₋₅-alkylamino-C₁₋₅-alkoxy, (C₃₋₆-cycloalkyl)methoxy, amino, C₁₋₅-alkylamino, di-C₁₋₅-alkylamino, anilino or N-1,3-dicyclohexylureido radical and R⁸ stands for a C₂₋₆-alkanoyl radical, and R², R³, R⁴ and R⁶ have the meanings stated in claim 1, and pharmaceutically-acceptable salts thereof, which comprises reacting a compound of the formula:—



wherein R², R³, R⁴, R⁵ and R⁶ have the meanings stated above, with a compound of the formula R¹Y, wherein R¹ has the meaning stated above and Y stands for a chlorine, bromine or iodine atom or a phenoxy radical, so as to give a compound of the formula:—



wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings stated above, and then ring-closing the said compound of the formula XVII so as to give the desired product of the formula I.

- 45 19. A process for the manufacture of the compounds of the formula I, wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated in claim 1 and R⁵ stands for a radical of the formula —COR⁷, wherein R⁷ stands for an

55

60

65

70

75

80

85

90

95

100

- 5 amino, C_{1-5} -alkylamino, di- C_{1-5} -alkylamino, anilino or hydrazino radical, and pharmaceutically-acceptable salts thereof, which comprises carrying out a known general process for making amides using as starting material a carboxylic acid of the formula I wherein R⁵ stands for a carboxy radical, or an acid halide, anhydride or nitrile thereof, so as to obtain the desired product.
- 10 20. A process for the manufacture of the compounds of the formula I, wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated in claim 1 and R⁵ stands for a radical of the formula —COR' wherein R' stands for a N-15 1,3-dicyclohexylureido radical, and pharmaceutically, acceptable salts thereof, which comprises reacting the corresponding carboxylic acid of the formula I, wherein R⁵ stands for a carboxy radical, with dicyclohexylcarbodiimide in a suitable organic solvent.
- 20 21. A process for the manufacture of the compounds of the formula I wherein R¹ contains one or two C_{1-5} -alkoxy substituents, R², R³, R⁴ and R⁶ have the meanings stated in claim 1, and R⁵ stands for a carboxy or hydroxymethyl radical, and pharmaceutically-acceptable salts thereof, which comprises reacting the corresponding compound of the formula I, wherein R¹ contains one or two active halogen substituents with an alkali metal derivative of a C_{1-5} -alkanol.
- 25 22. A process for the manufacture of compounds of the formula I wherein R¹, R², R³, R⁴ and R⁵ have the meanings stated in claim 1, and R⁶ stands for a C_{1-5} -alkoxy radical optionally together with a C_{1-5} -alkyl, cycloalkyl of not more than 5 carbon atoms, di- C_{1-5} -alkylamino or halogeno substituent, and pharmaceutically-acceptable salts thereof, which comprises reacting the corresponding compound of the formula I, wherein R⁶ stands for a hydroxy radical optionally together with an additional substituent as stated immediately above, or the corresponding alkali metal derivative, with a compound of the formula R¹²X, wherein R¹² stands for a C_{1-5} -alkyl radical and X stands for a halogen atom or a toluenesulphonyloxy or methanesulphonyloxy radical, and, in the case where the hydroxy derivative is used as reactant, in the presence of an acid-binding agent.
- 30 23. A process for the manufacture of the compounds of the formula I wherein R¹ bears a fluorine, chlorine or bromine substituent and R², R³, R⁴, R⁵ and R⁶ have the meanings stated above, apart from the case where R' stands for a hydrazino radical, and pharmaceutically-acceptable salts thereof, which comprises diazotising the corresponding compound of the formula I wherein R¹ bears an amino substituent, and then, in the case of the chloro or bromo substituent, reacting the diazonium salt with a solution of cuprous chloride or bromide in hydrochloric or hydrobromic acid respectively at 10 to 40°C., or, in the case of the fluoro substituent, thermally decomposing the dry diazonium fluoroborate salt at 40 to 100°C.
- 35 24. A process for the manufacture of the compounds of the formula I wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated in claim 1 and R⁵ stands for a hydroxymethyl radical, and pharmaceutically-acceptable salts thereof, which comprises reacting a corresponding ester of the formula I, wherein R⁵ stands for an alkoxy carbonyl, aralkoxy carbonyl or aryloxy carbonyl radical, with sodium borohydride, potassium borohydride or lithium aluminium hydride.
- 40 25. A process for the manufacture of the compounds of the formula I wherein R¹, R², R³, R⁴ and R⁶ have the meanings stated in claim 1 and R⁵ stands for a radical of the formula —CH₂OR', wherein R' stands for a C_{1-5} -alkanoyl radical, and pharmaceutically-acceptable salts thereof, which comprises acylating the corresponding compound of the formula I wherein R⁵ stands for a hydroxymethyl radical.
- 45 26. A pharmaceutical composition comprising a compound of the formula I, wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the meanings stated in claim 1, or a pharmaceutically-acceptable diluent or carrier.
- 50 27. A composition as claimed in claim 26 which is a dosage unit form, or a suppository, aqueous or non-aqueous solution or suspension, sterile injectable aqueous or non-aqueous solution, cream, lotion or ointment.
- 55 28. A dosage unit form as claimed in claim 27 which is a tablet or capsule, comprising 5 to 250 mg. of the said compound.
- 60 29. A composition as claimed in claim 26, 27 or 28 which contains, in addition to the said compound, at least one known agent having anti-inflammatory and/or analgesic activity.
- 30 30. A composition as claimed in any of claims 26 to 29 and intended for oral administration, which contains at least one antacid and/or a uricosuric agent.
- 35 31. A compound, claimed in claim 2, substantially as described in any of Examples 1 to 7.
- 40 32. A compound, claimed in claim 3, substantially as described in any of Examples 8 to 18.
- 45 33. A compound, claimed in claim 4, substantially as described in any of Examples 19 to 23.
- 50 65 70 75 80 85 90 95 100 105 110 115 120

34. A compound, claimed in claim 1, substantially as described in any of Examples 24 to 44.

R. ALLERTON,
Agent for the Applicants.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1974.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.



Pergamon

Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptor. Part 1: 2-Oxobenzothiazolin-3-acetic Acid Derivatives

Seiichiro Tabuchi,^a Hiromichi Itani,^a Yoshihiko Sakata,^b
Hiroko Oohashi^b and Yoshinari Satoh^{a,*}

^aMedicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan

^bMedicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan

Received 15 October 2001; accepted 9 February 2002

Abstract—Novel NPY-Y5 antagonist **FR73966** was discovered by screening of our in-house chemical library. The analogues were prepared by application of parallel synthesis techniques. Some of the resulting 2-oxobenzothiazolin-3-acetic acid derivatives exhibited nanomolar binding affinity for human NPY-Y5 receptors. © 2002 Elsevier Science Ltd. All rights reserved.

Neuropeptide Y (NPY) is a 36 amino acid peptide that was first isolated from porcine brain¹ and is found abundantly in the central and peripheral nervous system.^{2,3} NPY is involved in a number of physiological responses, such as food intake,^{4–6} blood pressure regulation,^{7,8} hormone secretion,⁹ sexual behavior,¹⁰ and circadian rhythm⁷ and is implicated in the pathophysiology of several disorders. For example, it has been reported that chronic injection of NPY in rats leads to severe overeating resulting to the development of obesity.⁶ Obesity is becoming a major health problem in advanced nations and even mild obesity enhances the risk of premature death, hypertension, diabetes mellitus, hyperlipidaemia, atherosclerosis, coronary heart disease, arthritis, sleep apnea and certain types of cancer.^{11,12} A strong association between obesity and non-insulin dependent diabetes mellitus (NIDDM) has been claimed, and more than 80% of NIDDM patients are known to be clinically obese.¹³ It is known that NPY-Y1 and -Y5 receptor subtypes in already cloned five

different receptor subtypes are activated according to centrally mediated NPY-induced feeding responses.^{14–17}

Recently, it has been reported that compounds which antagonize the Y5 receptor, for example CGP 71683A,¹⁸ Synaptic Pharm's tetralin derivative **1**,¹⁹ and α -substituted- β -aminotetralin **2**²⁰ (Fig. 1) is reported to be effective in reducing food intake in *ob/ob* mice and Zucker obese rat models.²¹

Consequently, we initiated a program to identify a novel chemical entity possessing Y5 receptor antagonistic activity for the treatment of obesity and eating disorders.

By screening of our in-house chemical library, we discovered 5-chloro-2-oxobenzothiazolin-3-acetic acid derivative **3** (**FR73966**) (Fig. 2), which showed high affinity ($IC_{50} = 53$ nM) for human Y5 receptors. This compound was attractive owing to the simple and novel




Figure 1.

*Corresponding author. Tel.: +81-6-6390-1376; fax: +81-6-6304-5435; e-mail: seiichiro_tabuchi@po.fujisawa.co.jp





Figure 2.



Scheme 1.




Figure 3.

chemical structure, and the preparation of its analogues might be possible by application of parallel synthesis techniques using amide formation reactions with many kinds of amines.

This letter describes the terminal amide formation by parallel synthesis techniques and the structure–activity relationships of the products in terms of potency as Y5 receptor antagonists.

We prepared various new derivatives **5** by reacting acid **4**, obtained easily by reaction of 5-chloro-2-oxo-benzothiazolin-3-acetic acid with isonipecotinic acid ester followed by alkali hydrolysis, with a variety of amines, as shown in Scheme 1.

The prepared derivatives were obtained as described below. Each reaction mixture was used directly for the assay after dilution with DMSO, because the yields in this amide formation were high and none of the starting materials, reagents and solvent DMF showed affinities for Y5 receptors.


1. Preparation of a 0.1 M solution of **4** in DMF for use in *n* parts, each containing 0.05 mM of **4**
2. Addition of TBTU (0.05 mM × 1.5 equiv × *n*)
3. Addition of *i*-Pr₂NEt (0.05 mM × 1.5 equiv × *n*)
4. Stirring for 1 h at ambient temperature
5. Separation of the obtained activated acid solution into *n* test tubes equipped with a sealed cap by using an Eppendorf pipetter
6. Addition of a 0.5 M solution of the desired amine in DMF (0.11 mL/0.05 mM × 1.1 equiv) into the test tubes
7. Heating each mixture at 50 °C overnight

8. Identification of the products by thin-layer chromatography and mass spectrometers
9. Transfer of each reaction mixture into a 96-well plate, dilution of each to 10⁻² M with DMSO and preservation in a refrigerator
10. Binding tests for Y5 receptor were performed after resolution of the preserved samples and further dilution with DMSO to 10⁻⁶–10⁻¹⁰ M concentrations.

About 300 derivatives were prepared by this parallel synthesis technique and compounds which showed IC₅₀ values less than 10 nM were synthesized by manual methods separately for confirming evaluation. The structures and biological evaluation results of the products in terms of potency as Y5 receptor antagonist are shown in Table 1, accompanied with those of manual synthesis products.

Unsubstituted anilide (**5a**) (Fig. 2) was more potent affinity for human Y5 receptors than the lead **FR73966**. Other primary anilides and naphthilides (**5b**–**5e**) showed also potent affinities but secondary cyclic anilides (**5f**, **5g**) were found to be weak. Furthermore, 4-substituted anilines, even when the substituents were hydrophilic or lipophilic, were more effective than the sterically hindered 2-substituted anilines (**5h**, **5i** > **5j**, **5k**). Meanwhile, heteroaromatic primary amides (**5l**–**5n**) generally showed potent affinities. In the case of using 4-methoxybenzyl, 4-sulfamoylphenethyl, 2-phenylethanol amines, the primary amide (**5o**–**5q**) were also found to have high affinities, but secondary amides (**5r**, **5s**), prepared with even a benzyl or a phenethyl type amines, showed little affinities, as similar to the structure–activity relationships of the anilides. It is conceivable that there is a

Table 1. Structure-activity relationships of 5.



Compd	$\text{HN}-\text{R}_1-\text{R}_2$	Inhibition % at				IC_{50} (nM) ^a
		10^{-6} M	10^{-7} M	10^{-8} M	10^{-9} M	
5b		108.3	99.0	83.4	49.3	0.71 ^b (17.0) ^c
5c		103.8	97.7	93.2	52.6	0.70 ^b (0.59) ^c
5d		102.3	101.2	80.5	45.3	1.4 ^b (0.89) ^c
5e		97.2	99.4	94.5	53.2	0.85 ^b (1.5) ^c
5f		51.4	59.8	-3.5	-4.5	—
5g		43.1	ND	43.1	ND	—
5h		84.7	101.3	74.6	28.7	2.9 ^b (1.7) ^c
5i		100.5	98.5	76.8	41.5	2.0 ^b (0.59) ^c
5j		95.0	91.4	41.1	5.6	1.4 ^b (4.7) ^c
5k		88.8	67.8	-5.3	-16.9	—
5l		94.0	88.5	70.3	29.9	2.6 ^b (2.3) ^c
5m		107.0	86.6	68.1	31.9	2.8 ^b (10.0) ^c
5n		86.2	101.7	68.4	16.5	4.7 ^b (3.8) ^c
5o		98.0	105	61.6	11.5	1.4 ^b (2.3) ^c
5p		102.0	88.8	44.7	19.5	9.0 ^b (6.1) ^c
5q		107.9	97.1	79.4	47.8	1.1 ^b (1.2) ^c
5r		77.2	15.6	ND	ND	—

Table 1 (continued)

Compd	R ₁	R ₂	10 ⁻⁶ M	10 ⁻⁷ M	10 ⁻⁸ M	10 ⁻⁹ M	IC ₅₀ (nM) ^a
5s			87.9	—3.9	ND	ND	—
5t			19.9	ND	ND	ND	—
5u			ND	14.5	ND	ND	—
5v			ND	106.2	89.6	ND	2.6 ^b (1.3) ^c

^aConcentration of compound that inhibited 50% of total specific binding of ¹²⁵I-PYY as a ligand to HEK 293 cells stably transfected with the human NPY-Y5 cDNA; obtained from the mean value of two experiments at each concentration (10⁻⁶–10⁻¹⁰ M).

^bIC₅₀ value of compound prepared by parallel synthesis technique.

^cIC₅₀ value of compound prepared by manual synthesis method.

hydrogen bond interaction between Y5 receptor and —CONH moiety of the ligand. Several compounds, amidated with aliphatic amines possessing a sulfonic acid or a methoxyethyl moiety (5t, 5u), showed little affinity for Y5 receptors. The other type of compounds, amidated with an amine containing an alkyl long chain, which are considered to have sufficient lipophilicity (5v), were surprisingly found to have potent affinities.

The most potent compound amongst those we prepared was **FR236478** (Fig. 3), with an IC₅₀ value of 0.23 nM. Unfortunately, this compound was poorly absorbed by po administration. We speculated that the poor absorption is due to its low solubility in water by high lipophilicity.

FR235208 (Fig. 3) showed one tenth potency (IC₅₀ = 3.3 nM) when compared with **FR236478**. Nevertheless it was sufficiently absorbed from a judgment of its plasma concentration (C_{max} = 15.7 µg/mL). But its poor permeability to brain was shown by *exo vivo* binding assay when orally administered at 100 mg/kg to rats.

Summary

Many 2-oxobenzothiazolin-3-acetic acid derivatives were prepared by parallel synthesis techniques around **FR73966**, novel structural lead compound discovered by screening of our in-house chemical library.

They showed potent antagonistic activity for human NPY-Y5 receptors. Some of them showed nanomolar binding affinities. Nevertheless, we are continuing our search for improved compounds, because the derivatives described in this letter have poor absorption and permeability to brain when orally administered.

Acknowledgement

The authors would like to acknowledge Dr. D. Barrett for helpful discussions and critical reading of the manuscript.

References and Notes

1. Takemoto, K.; Carlquist, M.; Mutt, V. *Nature* **1982**, *296*, 651.
2. O'Donohue, T. L.; Chronwall, B. M.; Pruss, R. M.; Mezey, E.; Kiss, J. Z.; Eiden, L. E.; Massari, J.; Tessel, E.; Pickel, V. M.; DiMaggio, D. A.; Hotchkiss, A. J.; Crowley, W. R.; Zukowska-Grojec, Z. *Peptides* **1985**, *6*, 755.
3. Takemoto, K.; Mann, M. J.; Shimizu, M. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89*, 1174.
4. Stanley, B. G.; Leibowitz, S. F. *Proc. Natl. Acad. Sci. U.S.A.* **1985**, *82*, 3940.
5. Kalra, S. P.; Dube, M. G.; Fournier, A.; Karla, P. S. *Physiol. Behav.* **1992**, *50*, 5.
6. Beck, B.; Stricker-Krongrad, A.; Nicolas, J.-P.; Burlet, C. *Int. J. Obesity* **1991**, *16*, 295.
7. Boublik, J. H.; Scott, N. A.; Brown, M. R.; River, J. E. *J. Med. Chem.* **1989**, *32*, 597.
8. Charmers, J.; Morris, M.; Kapoor, V.; Cain, M.; Elliot, J.; Russel, A.; Pilowsky, P.; Min-son, J.; West, M.; Wing, L. *Clin. Exp. Hypertens.* **1989**, *1*, 59.
9. Kalra, S. P.; Fuentes, M.; Fournier, A.; Parker, S. L.; Crowley, W. R. *Endocrinology* **1992**, *130*, 3323.
10. Clark, J. T.; Kalra, P. S.; Kalra, S. P. *Endocrinology* **1985**, *117*, 2435.
11. Olefsky, J. M. In *Harrison's Principles of Internal Medicine*, 13th ed.; Isselbacher, K. J., Braunwald, E., Wilson, J. D., Martin, J. B., Fauci, A. S., Kasper, D. L., Eds.; McGraw-Hill: New York, 1994, p 446.
12. Foster, D. W. In *Williams Textbook of Endocrinology*, 8th ed.; Wilson, J. D., Foster, D. W., Eds.; Saunders: Philadelphia, 1992, p 1335.
13. Wales, J. K. *Br. Med. J.* **1993**, *307*, 508.

14. Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, O.; Whitebread, S.; Hofbauer, K. G.; Taber, R. I.; Bracheck, T. A.; Weinshank, R. L. *Nature* 1996, 382, 168.
15. Inui, A. *Trends Pharmacol. Sci.* 1999, 20, 43.
16. Stanley, B. G.; Magdalin, W.; Seirafi, A.; Nguyen, M. M.; Leibowitz, S. F. *Peptides* 1992, 13, 581.
17. Kirby, D. A.; Koerber, S. C.; May, J. M.; Hagaman, C.; Cullen, M. J.; Pellymounter, M. A.; Rivier, J. E. *J. Med. Chem.* 1995, 38, 4579.
18. Rueger, H.; Schmidlin, T.; Rigollier, P.; Yamaguchi, Y.; Tintelnot-Blomley, M.; Schilling, W.; Criscione, L.; Mah, R. PCT WO 97/20823.
19. Islam, I.; Dhanoa, D. S.; Finn, J. M.; Du, P.; Gluchowski, C.; Jean, Y. T. PCT WO 97/19682.
20. (a) McNally, J. J.; Youngman, M. A.; Lovenberg, T. W.; Nepomuceno, D. H.; Wilson, S. J.; Dax, S. L. *Bioorg. Med. Chem. Lett.* 2000, 10, 213. (b) Youngman, M. A.; McNally, J. J.; Lovenberg, T. W.; Reitz, A. B.; Willard, N. M.; Nepomuceno, D. H.; Wilson, S. J.; Crooke, J. F.; Rosenthal, D.; Vaidya, A. H.; Dax, S. L. *J. Med. Chem.* 2000, 43, 346.
21. Hofbauer, K. G.; Schaffhauser, A. O.; Batzl-Hartmann, C.; Stricker-Krongrad, A.; White-Bread, S.; Cumin, F.; Rigollier, P.; Yamaguchi, Y.; Chiesi, M.; Levens, N.; Schillinf, W.; Walker, M. W.; Gerald, C.; Rueger, H.; Criscione, L. *Regul. Pept.* 1997, 71, 211.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.